

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
9 October 2003 (09.10.2003)

PCT

(10) International Publication Number  
WO 03/083132 A1

- (51) International Patent Classification<sup>7</sup>: C12Q 1/02, 1/68, G01N 33/00
- (21) International Application Number: PCT/SG03/00067
- (22) International Filing Date: 1 April 2003 (01.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/368,524 1 April 2002 (01.04.2002) US
- (71) Applicant and  
(72) Inventor: PAN, Shen, Quan [CN/SG]; 107 Clementi Road #06-01, Singapore 129790 (SG).
- (74) Agent: MIRZA KHALEEL NAMAZIE; c/o Tan Rajah & Cheah, 9 Battery Road #15-00, Straits Trading Building, Singapore 049910 (SG).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: VISULIZATION OF INTRODUCED DNA (VOID) IN TRANSIT BY IN SITU HYBRIDIZATION



(57) **Abstract:** The invention relates to a process for monitoring exogenous nucleic acid in transit. Once the nucleic acid has been introduced into the cell, cells are fixed permeabilized if necessary and subjected to in situ hybridization. The exogenous nucleic acid can thus be visualized in transit.

BEST AVAILABLE COPY

VISUALIZATION OF INTRODUCED DNA (VOID) IN TRANSIT BY *IN SITU*  
HYBRIDIZATION

10/510034

REFERENCE TO RELATED APPLICATIONS

5           This application claims the benefit of U.S. Provisional Application No. 60/368,524, filed April 1, 2002, the content of which is herein incorporated by reference.

FIELD OF INVENTION

10           The invention relates to a process for monitoring exogenous nucleic acid by *in situ* hybridization. The nucleic acid is monitored in transit once it has been introduced into a cell.

BACKGROUND OF THE INVENTION

15           Recombinant DNA technology can be used for various applications in the biomedical, agricultural, environmental, and industrial fields. These often require gene or DNA delivery and transformation. DNA molecules can be delivered into mammals as DNA vaccines. DNA molecules containing useful genes can be applied as therapeutics or so-called  
20           gene therapy. Genetic modifications of animal, plant or microbial organisms based on transgenic technology can lead to development of various high value products.

25           To develop these gene-based or DNA-based products, it is crucial to monitor the gene (DNA) delivery and transformation processes and efficiencies. Current techniques for this purpose are based on detection of the expressed gene product of the DNA delivered. Therefore, marker or reporter genes are used for the detection of gene delivery and transformation. To allow the marker or  
30           reporter gene to be expressed, appropriate promoters that can drive the expression of the delivered gene have to be included. However, a promoter may not be functional in certain cell type(s), stage(s), and/or condition(s). The

activity of a promoter in certain cell type(s), stage(s), and/or condition(s) may be too weak for the detection. Alternatively, the activity may be so strong that it can lead to the toxicity of a marker or reporter gene. In addition, enough time has to be given to the marker or reporter gene to be expressed. This can considerably prolong the time needed to develop DNA-based or gene-based products.

Inclusion of the marker or reporter gene(s) in a gene-based or DNA-based product may also harm public acceptance of the product, because of the potential effects of the marker or reporter gene(s) or its product(s) on the environment and human health. Furthermore, detection of the marker or reporter protein cannot readily reveal the transgene copy numbers or locations of the desired DNA, which are important for assessing the efficacy and safety of the material containing the desired DNA. This is because having too many copies of the transgene delivered into the target cells may lead to unwanted integration at vital sites of the host chromosomes, which could be harmful to the host.

*In situ* hybridization is a technique which uses direct hybridization of a DNA probe with DNA or RNA in biological structures, typically permeabilized cells, subcellular fractions, or fixed chromosome preparations. The technique is often directed toward a target sequence in a double-stranded duplex nucleic acid, typically a DNA duplex associated with a pathogen or with a selected sequence in viral or cell chromosomal DNA. A single-stranded labeled probe is annealed to the denatured target duplex nucleic acid, and the structure is processed for visualization of the annealed probe, thus allowing the location of the probe within the target duplex nucleic acid to be determined.

*In situ* hybridization has been used to reveal morphological information about the localization of sequence-specific targets in fixed biological structure. Specifically the method has been widely applied to

5 chromosomal DNA, for mapping the location of specific gene sequences, and distances between known gene sequences, for studying chromosomal distribution of satellite or repeated DNA, for examining nuclear organization, for analyzing chromosomal aberrations, for localizing DNA damage in single

10 cells or tissue and for determining chromosome content by flow cytometric analysis. Localization of integrated viral sequences within host-cell chromosomes have been reported. The method has also been used to study the position of chromosomes, by three-dimensional reconstruction of

15 sectioned nuclei, and by double *in situ* hybridization with mercurated and biotinylated probes, using digital image analysis to study interphase chromosome topography. *In situ* hybridization has also been used to detect the presence of virus in host cells, as a diagnostic tool.

20 Cheng L, Bucana CD, Wei Q. Fluorescence *in situ* hybridization method for measuring transfection efficiency. *Biotechniques* 1996 Sep; 21(3):486-91, states "We describe here the use of fluorescence *in situ* hybridization (FISH) to measure the transfection efficiency of the transient

25 expression vector pCMVcat in lymphoblasts and fibroblasts." Cheng et al. showed that, for transfection of pCMVcat by the diethylaminoethyl-dextran method, the transfection efficiency was about 15 and 70 times greater in fibroblasts and lymphoblasts, respectively, when measured by FISH as

30 compared to the efficiency measured by cotransfection with pCMV beta gal.

In Co DO, Borowski AH, Leung JD, van der Kaa J, Hengst S, Platenburg GJ, Pieper FR, Perez CF, Jirik FR, Drayer JI. Generation of transgenic mice and germline

transmission of a mammalian artificial chromosome introduced into embryos by pronuclear microinjection. Chromosome Res 2000;8(3):183-91, transgenic mice were generated by pronuclear microinjection of a murine satellite DNA-based artificial chromosome (SATAC). FISH analyses of metaphase chromosomes from mitogen-activated peripheral blood lymphocytes from both the founder and progeny revealed that the SATAC was maintained as a discrete chromosome and that it had not integrated into an endogenous chromosome.

Collas P, Alestrom P. Nuclear localization signals enhance germline transmission of a transgene in zebrafish. Transgenic Res 1998 Jul;7(4):303-9 reported that cytoplasmic injection into zebrafish eggs of plasmid DNA complexed to nuclear localization signal (NLS) peptides increased nuclear uptake of transgene DNA early during embryo development. It states that "Monitoring the dynamics of nuclear uptake of DNA-NLS complexes by fluorescence in situ hybridization (FISH) of interphase nuclei indicates that NLS enhances both the proportion of nuclei importing DNA during early embryo development, and the amount of DNA imported by individual nuclei."

#### SUMMARY OF THE INVENTION

The invention relates to the use of a modified *in situ* hybridization procedure to monitor the progress of introduced nucleic acid as it makes its way into the cell, through the cytoplasm and into the nucleus. In the past, *in situ* hybridization has been used to visualize introduced DNA at its endpoint; for example, DNA after it has integrated into a chromosome, or episomal DNA once it has reached the point where it has become replicated and/or has reached the nucleus and can be expressed (transcribed). The present invention relates to visualizing the nucleic acid in transit, prior to, or just as it reaches, its endpoint. The

process is useful for defining the optimum parameters for nucleic acid delivery under a given set of conditions.

The process is termed Visualization Of Introduced DNA (VOID). Once the nucleic acid has been introduced into a cell in a biological sample, the cells are fixed and optionally permeabilized if necessary, then subjected to an *in situ* hybridization procedure in which the fixed cells are contacted with a probe which hybridizes to the exogenous nucleic acid. The exogenous nucleic acid, in transit, can thus be visualized.

Although the abbreviation "VOID" refers to DNA, the process is clearly applicable to any introduced nucleic acid including RNA.

In one embodiment, the nucleic acid is DNA. In another embodiment, the nucleic acid is DNA and is introduced into the cell by *Agrobacterium*.

*In situ* hybridization may be fluorescence *in situ* hybridization, radioactive *in situ* hybridization, or enzymatic *in situ* hybridization.

In one aspect, the process described above may be used to determine the number of exogenous nucleic acid in the cytoplasm or in the nucleus.

In another aspect, the process described above may be used to determine whether the exogenous nucleic acid is in the cytoplasm or the nucleus.

In another aspect, the process described above may be used to determine the length of time required for the exogenous nucleic acid to appear in the cytoplasm.

In another aspect, the process described above may be used to determine how long it takes for the exogenous nucleic acid to reach the nucleus from the cytoplasm.

In another aspect, the process described above may be used to determine the efficiency of delivery of the nucleic acid into the nucleus. This process would further comprise the step of measuring the ratio of the number of  
5 the exogenous nucleic acid in the nucleus to the number of the exogenous nucleic acid in the cytoplasm.

In another aspect, the process described above may be used to assess risk associated with introduction of the exogenous nucleic acid into the cell, including the risk  
10 associated with the use of a particular vehicle for nucleic acid delivery such as a particular vector system. This process further comprises the step of determining the number of exogenous nucleic acid in the cytoplasm and in the nucleus at different time intervals after the exogenous  
15 nucleic acid has been introduced. The ratio of exogenous nucleic acid in the nucleus to cytoplasm is determined at each interval. This allows VOID to predict, in accordance with said ratio and number of exogenous nucleic acid introduced, the risk associated with introduction of the  
20 exogenous nucleic acid into the cell or with the use of a particular vehicle for nucleic acid delivery.

In another aspect, the process described above may be used to control the copy number of the exogenous nucleic acid introduced into the cell.

25 In another aspect, there is described a process for determining the proportion of cells competent to receive exogenous nucleic acid. The process comprises:  
(a) introducing an exogenous nucleic acid to a portion of a population of cells; (b) monitoring the exogenous nucleic  
30 acid according to the process described above to determine the presence of the exogenous nucleic acid in the cell; and  
(c) determining the number of cells in which the exogenous nucleic acid is present. The proportion of cells which contain the exogenous nucleic acid as observed with VOID

reflects the proportion of cells competent to receive the exogenous nucleic acid.

In another aspect, VOID may be used to identify whether a cell contains an exogenous nucleic acid, without  
5 having to use a selection marker or reporter protein. The process comprises: (a) introducing the exogenous nucleic acid into the cell; and (b) monitoring the exogenous nucleic acid according to the process described above. Visualization of the nucleic acid in the cell indicates that the cell  
10 contains the exogenous nucleic acid.

In another aspect, VOID may be used to identify a molecular marker associated with the competency of a cell to receive exogenous nucleic acid. The process comprises: (a) introducing an exogenous nucleic acid to the cell; (b)  
15 monitoring the exogenous nucleic acid according to the process described above; (c) testing the fixed cells for binding of a cellular antigen with an antibody. The antibody should be capable of binding to the antigen in the fixed and permeabilized cell; and (d) determining whether  
20 the antigen co-localizes with the exogenous nucleic acid in transit. Co-localization of the exogenous nucleic acid in transit with the antigen would indicate that the antigen is a molecular marker associated with transformation competency.

25 In another aspect, VOID may be used to determine the optimum parameters for obtaining a desired copy number of exogenous nucleic acid introduced into the cell, the process comprising: (a) introducing an exogenous nucleic acid into a cell under a set of parameters; (b) monitoring  
30 the exogenous nucleic acid according to the process described above to determine the number of exogenous nucleic acid in the cytoplasm or in the nucleus at different time intervals after the nucleic acid has been introduced; and (c) determining the set of parameters under which the



exogenous nucleic acid is delivered in the desired copy number into the cell. In one embodiment, at least one of the parameters is the length of time in which the exogenous nucleic acid is in contact with the cell.

5           In another aspect, VOID may be used to identify a cell that is competent for receiving exogenous nucleic acid, the process comprising monitoring the exogenous nucleic acid according to the process described above for presence of the exogenous nucleic acid in the cell.

10           In another aspect, VOID is used to identify a cell competent to receive exogenous nucleic acid. The process comprises identifying expression of a Sec3 protein in the cell. Sec3 expression would indicate that the cell is competent to receive exogenous nucleic acid. In one  
15           embodiment, the cell is a plant cell and the Sec3 protein is VirD2-Interacting protein (VDI).

          In another aspect, there is described a process for producing cells competent to receive exogenous nucleic acid, the process comprising the step of expressing Sec3  
20           protein in the cell under control of an inducible promoter.

          In another aspect, VOID is used to identify a cell competent to receive exogenous nucleic acid. The process comprises the step of identifying expression of a component of Exocyst complex in the cell. Expression of the component  
25           indicates that the cell is competent to receive exogenous nucleic acid.

          In another aspect there is described a kit for monitoring exogenous nucleic acid in transit, the nucleic acid having been introduced into a cell. The kit comprises:  
30           (a) reagents for fixing the cells; (b) reagents for permeabilizing the fixed cells; (c) reagents for *in situ* hybridization of a probe with the exogenous nucleic acid;

and (d) instructions for using the reagents (a) to (c) to monitor the exogenous nucleic acid in transit.

In one embodiment, the processes described above are applied to plant cells. Such processes may further  
5 comprise the step of removing the cell wall.

#### DESCRIPTION OF THE DRAWINGS

Various embodiments of the invention are illustrated by way of the figures described below. The figures are originally in color. The various symbols are  
10 used to indicate the colored objects observed in figures which are not printed in color.

Fig. 1. Schematic presentation of relevant gene constructs in *A. tumefaciens*. The Ti plasmid contains the *vir* genes (*virA-E* and *virG*) that are required for the transfer of T-DNA harbored on pIG121-Hm (Ohta S. et al. 1990. Construction and expression in tobacco of a  $\beta$ -Glucuronidase (GUS) reporter gene containing an intron within the coding sequence. Plant Cell Physiol., 31(6), 805-813) and delineated by the left (LB) and right border (RB). The T-DNA contains the GUS gene driven by the 35S promoter (P<sub>35S</sub>).  
20 The small arrows indicate the primers used to amplify PCR fragments, which were labeled as probes for VOID. Primers GUS-1 (5'-CGTCCTGTAGAAACC-3'; SEQ ID NO:2) and GUS-2 (5'-ACGCACAGTTCATAG-3'; SEQ ID NO:3) were used to generate a  
25 755-bp fragment, which can be used as the T-DNA probe to detect T-DNA inside plant cells. Primers BIN19-1 (5'-TTGCTCATGTTACCG-3'; SEQ ID NO:4) and BIN19-2 (5'-GCAGTTCGCAAATA-3'; SEQ ID NO:5) were used to generate a  
30 757-bp fragment, which can be used as the vector backbone probe to detect the presence of the plasmid backbone. Primers Oligo-105 (5'-GAAGAATTGGAAGTTGACGCCGATACC-3'; SEQ ID NO:6) and Oligo-107 (5'-AGGCTGCAGACATGCGTATTTTCG-3'; SEQ ID NO:7) were used to generate a 677-bp fragment, which can be

used as the *aopB* probe to detect the presence of *A. tumefaciens* chromosomal DNA.

Fig. 2. The requirements for visualization of T-DNA inside plant cells. The BY2 cells were cocultivated with  
5 LBA4404(pIG121-Hm) (*vir*<sup>+</sup>) (panels A, D and F), MX243(pIG121-Hm) (*virB*<sup>-</sup>) (panel B), WR1715(pIG121-Hm) (*virD2*<sup>-</sup>) (panel C), or MX358(pIG121-Hm) (*virE2*<sup>-</sup>) (panel E) for 1 day. They were then subjected to the VOID procedure using the T-DNA (panels A, B, C and E), *aopB* (panel D) or vector backbone (panel F)  
10 probes (Fig. 1). Confocal microscopy was conducted to reveal specific DNA hybridization, which generated the red dots (arrowed). The green fluorescence (arrowhead) indicated BY2 nuclei stained with PicoGreen. Red fluorescence, green fluorescence and transmission images  
15 were overlapped for each panel.

Fig. 3. Visualization of plant nuclear DNA molecules and numbers of T-DNA molecules inside plant cells. The BY2 cells were cocultivated with LBA4404(pIG121-Hm) for 1 d and subjected to the VOID procedure using the plant DNA [which  
20 was a 904-bp *EcoRI* fragment of an *Arabidopsis thaliana* cDNA clone (corresponding to F16N3.18 of the genome sequence)] (panels A and B) or T-DNA (panel C) probe (Fig. 1). Confocal microscopy was conducted to reveal specific DNA hybridization, which generated the red dots (arrowed). The  
25 green fluorescence (arrowhead) indicated BY2 nuclei stained with PicoGreen. Red and green fluorescence images were overlapped (panels A and C). To clearly reveal red dots, only red fluorescence image was shown in panel B. To count numbers of T-DNA molecules inside BY2 cells, individual BY2  
30 cells were reconstituted by overlapping sequential 1- $\mu$ m-laser-sections of confocal microscopy (panel C); the white bar denotes 10  $\mu$ m.

Fig. 4. Time course of T-DNA trafficking inside plant cells. The BY2 cells were cocultivated with LBA4404 (pIG121-Hm) for 0 h (panel A), 2 h (panel B), 5 h (panel C), 1 d (panel D), 2 d (panel E), or 3 d (panel F). They were then subjected to the VOID procedure using the T-DNA probe (Fig. 1). Confocal microscopy was conducted to reveal specific DNA hybridization, which generated the red dots (arrowed). The green fluorescence (arrowhead) indicated BY2 nuclei stained with PicoGreen. Red fluorescence, green fluorescence and transmission images were overlapped for each panel.

Fig. 5. Localization of VDI protein (SEQ ID NO:1) in tobacco BY2 and *Arabidopsis thaliana* cells. Tobacco BY2 cells (A) and *A. thaliana* (B) cells were fixed and then subjected to the immunohistology using anti-VDI as the primary antibody and anti-rabbit IgG-Cy3 as the secondary antibody. Confocal microscopy was conducted to reveal the localization of VDI, which generated the red dots (arrowed). The green fluorescence (arrowhead) indicated BY2 nuclei stained with PicoGreen. Red fluorescence, green fluorescence and transmission images were overlapped for each panel. There were not any significant signals detectable in the negative control (C) when preimmune serum instead of anti-VDI was used. The VDI was located in the cytoplasm of cells and only existed in some cells.

Fig. 6. GUS staining of tobacco BY2 cells. Tobacco BY2 cells were cocultivated with (A) or without (B) preinduced LBA4404 (pIG121-Hm) for 3 days and were then subjected to the GUS assay. Samples were then viewed under light microscopy. The blue color spots (arrowhead) represented the GUS activity, which indicated that clusters of cells were transformed by *A. tumefaciens*. Only some plant cells were transformed by *A. tumefaciens* and gave blue color spots. Bar represents 126  $\mu\text{m}$ .

Fig. 7. Coexistence of VDI and GUS protein in the same transformed BY2 cells. Tobacco BY2 cells were cocultivated with preinduced LBA4404 (pIG121-Hm) (A) or MX243 (pIG121-Hm) (B) for 3 days. They were then subjected to the double immunohistology assay. Confocal microscopy was conducted to reveal the location of VDI and GUS protein, which generated the red dots (arrowed) and green dots (arrowhead), respectively. Red fluorescence, green fluorescence and transmission images were overlapped for each panel.

Coexistence of VDI and GUS in the same transformed BY2 cells indicated that only those cells producing VDI protein could be transformed by *A. tumefaciens*.

Fig. 8. Colocalization of VDI protein and T-DNA molecules in the same transformed BY2 cells. Tobacco BY2 cells were cocultivated with LBA4404 (pIG121-Hm) (A) or MX243 (pIG121-Hm) (B) for 1 day. They were then subjected to VOID followed by immunohistology. Confocal microscopy was conducted to reveal the location of VDI and T-DNA, which generated the red dots (arrowed) and green dots (arrowhead), respectively. Red fluorescence, green fluorescence and transmission images were overlapped for each panel. Colocalization of VDI and T-DNA in the same transformed BY2 cells indicated that only those cells producing VDI protein could receive T-DNA delivered by *Agrobacterium*.

Fig. 9: Sequence homology between VirD2-Interacting protein (VDI; SEQ ID NO:1) and various members of the Sec3 family, including human Sec3 (SEQ ID NO:8), rat Sec3 (SEQ ID NO:9), mouse Sec3 (SEQ ID NO:10), and fruit fly Sec3 (SEQ ID NO:11).

#### DETAILED DESCRIPTION OF THE EMBODIMENTS

The invention is applicable to the monitoring of any exogenous nucleic acid in transit in a cell-containing biological sample.

The nucleic acid may be any DNA or RNA which has been introduced into the cell. By "exogenous nucleic acid" is meant any nucleic acid which is not already in the cell. The term encompasses nucleic acids such as plasmid  
5 constructs, viral nucleic acids, episomal DNA and cassettes, artificial chromosomes and naked DNA, which contain a sequence which is not already present in the cell. It is contemplated that the invention also applies to the monitoring of nuclear fusion, where the DNA of one nucleus  
10 is distinguishable in sequence from the DNA of the other nucleus.

The exogenous nucleic acid is the target for *in situ* hybridization and may be any introduced DNA target, or may be an introduced RNA such as the genome of RNA viruses  
15 or RNA introduced by a retrovirus. The target may also be a nucleic acid which has been amplified by means such as the polymerase chain reaction (PCR), so that additional copies of the nucleic acid targets are produced.

The term "biological sample" includes, but is not  
20 limited to, samples of human, animal, microbial or plant origin such as human, animal, microbial or plant tissue sections, cell or tissue cultures, suspension of human, animal or plant cells or isolated parts thereof, human or animal biopsies, blood samples, cell-containing fluids and  
25 secretion. The introduced nucleic acids in whole cells contained in the biological sample are observed, not subcellular fractions.

#### **Visualization Of Introduced DNA (VOID)**

The invention relates to the monitoring of nucleic  
30 acid in transit, after it has been introduced into the cell and as it progresses toward its endpoint. The nucleic acid is visualized while it is in flux, before or just as it reaches its endpoint. The endpoint is usually when the

introduced nucleic acid is in the nucleus and becomes integrated into or associated with the host cell chromosomes, or engages the transcription machinery for expression, or engages the cellular mechanism for self-replication. While it is understood that no living cell is actually static at any point, by "in transit" is meant the progression of the introduced nucleic acid towards its equilibrium or stable state at its endpoint location in the cell. Usually this endpoint location is the nucleus of the cell into which the nucleic acid has been introduced.

The exogenous nucleic acid may be introduced into the cell by any means known in the art. The term "introduce" is sometimes used interchangeably in the art with "transform" or "transfect". Methods for transforming / transfecting host cells with expression vectors are well-known in the art and depend on the host system selected as described in Ausubel et al., (Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons Inc., 1994). Means for introducing exogenous nucleic acids into cells include, but are not limited to, electroporation (see for example US patent 5,273,525); liposome-mediated and lipoprotein mediated delivery (see for example US patent 6,468,798); viral delivery systems such as retroviral vectors (see for example US patent 6,410,313), adeno associated viral vectors (see for example US patent 6,153,436), herpes simplex viral vectors, and bacteriophage vectors (see for example US patent 6,054,312); cationic peptide mediated delivery (see for example US patent 6,387,700); microneedle injection (see for example US patent 5,697,901); microparticle bombardment and *Agrobacterium*-mediated gene delivery, especially in plants (see for example US patent 5,932,782); and microinjection into the nucleus (see for example US patent 6,498,285). The nucleic acid may be introduced first into the cytoplasm through the plasma membrane, or directly into the nucleus through the

nuclear membrane. In a preferred embodiment, the nucleic acid is introduced into the cytoplasm through the plasma membrane.

Although the actual experiments described here relate to *Agrobacterium*-mediated transformation of tobacco cells, VOID should be applicable to all eukaryotic cells, such as plant, yeast, fungal and animal cells, including human cells, using any kind of nucleic delivery method known in the art and as described above.

In one embodiment, DNA is introduced into the target cells by *Agrobacterium*-mediated transformation. In nature, *A. tumefaciens* is a soil-borne bacterium that causes crown gall tumours on many plant species, particularly dicot plants. The bacterium transfers a specific segment (T-DNA) of its tumour-inducing (Ti) plasmid into plant cells, where the T-DNA becomes integrated into the plant genome (Christie, P. J., 2001. *Mol. Microbiol.*, 40(2), 294-305; Gelvin, S. B., 2000. *Annu. Rev. Plant Physiol. Plant Mol. Biol.*, 51, 223-256; Zhu et al. 2000. *J. Bacteriol.*, 182, 3885-3895; Zupan et al. 2000. *Plant J.*, 23, 11-28). The T-DNA contains the oncogenes that cause overproduction of plant hormones and hence tumours. Therefore, *Agrobacterium* is a natural genetic engineer that transforms plants with its own genes for its own benefits.

The virulence (*vir*) genes located on the Ti plasmid are directly responsible for the T-DNA transfer process. The *Agrobacterium* genome has been sequenced. Transformation using *Agrobacterium* has been modified such that useful genes can be introduced into many plant species without causing tumours. Recently, it has been demonstrated that *Agrobacterium* can also transfer DNA into yeast, fungal and mammalian cells (P. Bundock et al. *EMBO J.* 14:3206 (1995); K. L. Piers et al. *Proc. Natl. Acad. Sci. USA.* 93:1613 (1996); M. J. de Groot et al. *Nat. Biotechnol.*



16:839 (1998); T. Kunik et al. *Proc. Natl. Acad. Sci. U.S.A.*  
98:1871 (2001)). This suggests that this system can be  
adopted for other eukaryotic cells.

The *Agrobacterium* system has several features that  
5 make it very attractive as a general gene transfer vector.  
As the integration occurs at fairly random positions, the T-  
DNA can be used as a tagging vector. The T-DNA can be also  
targeted to a specific site in the genome by homologous  
recombination. Due to the accompanying VirD2 and VirE2  
10 proteins, the T-DNA is well preserved during its passage to  
the nucleus. The transformation is highly efficient due to  
the nuclear targeting by the nuclear localization signals of  
VirD2 and VirE2. These nuclear localization signals are  
well conserved among eukaryotic cells.

15 VirD2 is an *Agrobacterium* virulence gene encoded  
protein that plays multiple important roles in the transfer  
of T-DNA. First, VirD2 serves as an endonuclease that  
cleaves the bacterial T-DNA at the border sequences. After  
cleavage, the VirD2 protein remains covalently attached to  
20 the 5' end of the T-strand. This would enable the VirD2  
protein to serve as a pilot protein that guides the passage  
of the T-strand from *Agrobacterium* into plant cells.

There are a number of plant proteins that  
specifically interact with VirD2. These proteins are well  
25 conserved in the eukaryotic cells, including plant, yeast,  
fungal and animals cells. Since T-DNA can be delivered by  
the bacterium into plant, yeast, fungal and mammalian cell  
nuclei, this suggests that the DNA trafficking pathway is  
well conserved among eukaryotic cells.

30 The structure of the integrated T-DNA is similar  
regardless of the host genome wherein the integration took  
place. This indicates that the same molecular mechanism of  
T-DNA integration is used by different eukaryotic species.

Recently the proteins that mediate non-homologous T-DNA integration have been identified using the yeast *Saccharomyces cerevisiae* as a model. These included the yeast Ku70 - Ku80 heterodimer, DNA ligase IV and the Mre11, Xrs2, Rad50 complex. These proteins are all known to be involved in double strand break (DSB) repair by non-homologous end-joining. As these proteins are conserved in other eukaryotes including animals and plants, this suggests that the same mechanism of non-homologous T-DNA integration is used by all species studied so far. This demonstrates that *Agrobacterium* delivery of T-DNA offers an feasible system to study DNA trafficking and DSB repair in eukaryotic cells.

#### Sample preparation

At various intervals after the nucleic acid is introduced into the cell, the cell is treated in preparation for *in situ* hybridization. The appropriate treatment will depend on the type of sample to be examined, as known in the art. During the treatment, the sample will be subject to fixation and, if required, permeabilization.

In one aspect of the invention, the sample is deposited onto a solid support. The particular techniques appropriate for depositing the sample depends on the type of sample. Such techniques include, for example, sectioning of tissue as well as smearing or cytocentrifugation of cell suspensions.

The types of solid supports are known in the art. Supports which may be utilized include, but are not limited to, microporous beads or sponges, glass, Scotch tape (3M), nylon, Gene Screen Plus (New England Nuclear), magnetic particles and nitrocellulose. Most preferably glass microscope slides are used. The use of these supports and the procedures for depositing specimens thereon are known in

the art. The choice of support material will depend upon need for the procedure used to visualize or analyze cells and the quantitation procedure used. Some filter materials are not uniformly thick and, thus, shrinking and swelling during *in situ* hybridization procedures is not uniform. In addition, some supports which autofluoresce will interfere with the determination of low level fluorescence. Glass microscope slides are most preferable as a solid support since they have high signal-to-noise ratios and can be treated to better retain tissue.

Prior to hybridization, the sample is suitably treated with various chemicals to facilitate the subsequent reactions. The actual pretreatment will depend on the type of sample to be analysed and on whether DNA or RNA sequences are to be detected. For monitoring RNA, the sample may need to be treated as soon as possible after the RNA is introduced into the cell. It may be advantageous to treat the sample with DNase to minimise the background noise when the target sequence is RNA. By fixing the cells in the sample, the morphological integrity of the cellular matrix and of the nucleic acids within the cell is preserved.

Fixing may be by means of chemical fixation or freezing. When freezing is used for preservation of a sample, the sample may be frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$ . Prior to the analysis of the nucleic acid, the frozen sample is cut into thin sections and transferred to e.g. pre-treated slides. This can e.g. be carried out at a temperature of  $-20^{\circ}\text{C}$  in a cryostat. The tissue sections may suitably be stored at  $-80^{\circ}\text{C}$  until use.

In preparation for hybridization, the biological sample may be treated with a fixative, including a precipitating fixative such as acetone. Alternatively, the biological sample is incubated for a short period in a solution of buffered formaldehyde. The biological sample

can also be transferred to a fixative such as buffered formaldehyde for 12 to 24 hours. Following fixation, the biological sample may be embedded in paraffin forming a block from which thin sections can be cut.

5               Fixatives are compounds that kill a cell but preserve its morphology and/or nucleic acids for an extended period of time. They act either by creating covalent linkages between cellular molecules or by precipitating certain intracellular molecules. Cross-linking fixatives  
10 include formaldehyde, glutaraldehyde, paraformaldehyde, ethyldimethyl-aminopropyl-carbodiimide, and dimethylsilserimide. Precipitants include ethanol, acetic acid, methanol, acetone, and combinations thereof. It is further preferred that glacial acetic acid be included as a  
15 fixative when the cells are to be monitored by flow cytometry. If a cross-linking fixative is used, paraformaldehyde (0.1% v/v to 4% v/v is preferred, 0.5% v/v to 1% v/v is especially preferred; 2 hours to 20 hours preferred). Formaldehyde and glutaraldehyde are among the  
20 other possibilities. Fixatives are used at concentrations which do not destroy the ability of the cell's nucleic acids to hybridize to the probe. Fixatives and hybridization of fixed cells, in general, are discussed in WO 90/02173 and WO 90/02204. See also US patents 5,719,023, US 5,888,733 and  
25 US 5,521,061 for general discussions of *in vitro* hybridization.

Prior to hybridization, the biological sample may be de-waxed and rehydrated using standard procedures.

For all sample preparation, the nucleic acids are  
30 fixed in morphological relationship with cellular structure allowing hybridization to be carried out *in situ*. The nucleic acids are not extracted from the cellular material and hybridization is not carried out in solution.

If RNA sequences are the target for hybridization, degradation by ribonucleases during the prehybridization steps should be avoided. All equipment and solutions used for pretreatment as well as for hybridization should be  
5 appropriately treated to remove nucleases. Such inactivation techniques are well known in the literature and may be performed according to standard procedures.

In preparing a biological sample for *in situ* hybridization, it may be necessary to treat the sample so as  
10 to permeabilize the material and preserve the morphology.

Permeabilization may be necessary in order to ensure sufficient accessibility of the probe to the target nucleic acid sequences. The type of treatment will depend on several factors, for instance on the fixative used, the  
15 extent of fixation, the type and size of sample used and the length of the probe. The treatment may involve exposure to protease such as proteinase K, pronase or pepsin, diluted acids, detergents or alcohols or a heat treatment.

For biological samples such as plant where the  
20 cells have cell walls, it may be necessary to remove the cell wall to allow the probe access to the target nucleic acid. The cell wall may be removed by digestion with a cell wall-digesting enzyme such as cellulase. In one embodiment, the cell wall is removed after the cells have been fixed,  
25 but before permeabilization.

Permeabilizing agents include, but are not limited to, detergents such as Brij 35, Brij 58, sodium dodecyl sulfate, CHAPS, and TRITON X-100. Depending on the location of the target nucleic acid, the permeabilizing agent is  
30 chosen to facilitate probe entry through the cell membranes, preferably the plasma membrane. For instance, 0.05% Brij 35 or 0.1% TRITON X-100 will permit probe entry through the plasma membrane but not the nuclear membrane.

Alternatively, sodium deoxycholate will allow probes to traverse the nuclear membrane. Thus, in order to restrict hybridization to the cytoplasmic structures, nuclear membrane permeabilizing agents are avoided. Such selective subcellular localization may improve the specificity and sensitivity of detection by minimizing probe hybridization to complementary nuclear sequences when the target sequence is located in the cytoplasm.

### In situ hybridization

*In situ* hybridization may be performed using any of the methods known in the art (see Jong et al 1999. High resolution FISH in plants - techniques and applications. Trends in Plant Science, 4, 258-263 and Nath J and Johnson KL 2000. A review of fluorescence in situ hybridization (FISH): Current status and future prospects. Biotech Histochem 75: 54-78). The basic steps involve hybridization of a probe to the exogenous nucleic acid, washing the sample to remove non-specific binding, and visualizing the bound probe.

A probe is defined as genetic material DNA, RNA, or oligonucleotides or polynucleotides comprised of DNA or RNA. The DNA or RNA may be composed of the bases adenosine, uridine, thymidine, guanine, cytosine, or any natural or artificial chemical derivatives thereof. The probe is capable of binding to a complementary or mirror image target nucleic acid through one or more types of chemical bonds, usually through hydrogen bond formation. The extent of binding is referred to as the amount of mismatch allowed in the binding or hybridization process; the extent of binding of the probe to the target sequences also relates to the degree of complementarity to the target sequences. The size of the probe is adjusted to be of such size that it forms stable hybrids at the desired level of mismatch; typically, to detect a single base mismatch requires a probe of

approximately 12-50 bases. Larger probes (from 50 bases up to tens of thousands of bases) are more often used when the level of mismatch is measured in terms of overall percentage of similarity of the probe to the target cellular genetic sequence. The size of the probe may also be varied to allow or prevent the probe from entering or binding to various regions of the genetic material or of the cell. Similarly, the type of the probe (for example, using RNA versus DNA) may accomplish these objectives. The size of the probe also affects the rate of probe diffusion, probability of finding a cellular target match, etc.

The length of a probe affects its diffusion rate, the rate of hybrid formation, and the stability of hybrids. As a general guide, to detect target RNA, small probes (50-150 bases) may allow the most sensitive, rapid and stable signal. A mixture of short probes (50-150 bases) are prepared which span the entire length of the target sequence. For example, if the target sequence were 1000 bases long, about 10-20 "different" probes of 50-100 bases would be used in the hybrid solution to completely cover all regions of the target sequence. To detect target DNA, smaller probes (15-50 bases) may be utilized.

The concentration of the probe affects several parameters of the *in situ* hybridization reaction. High concentrations are used to increase diffusion, to reduce the time of the hybridization reaction, and to saturate the available cellular sequences. In an embodiment, probe concentrations of 1-10  $\mu\text{g/ml}$  or 2.5  $\mu\text{g/ml}$  are used.

Nucleic acid probes can be prepared by a variety of methods known in the art. The probe may be constructed or obtained by one of a number of standard methods. Many probes, such as various satellite DNA sequences are commercially available in single-stranded or double-stranded form. Other probes can be obtained either directly from

viruses, plasmids and cosmids or other vectors carrying specific sequences, or, if desired, by restriction digest of the source of the probe DNA, such as a vector, followed by electrophoretic isolation of specific restriction digestion  
5 fragments. Probes obtained in this manner are typically in double-stranded form, but may, if required, be subcloned in single-stranded vectors, such as an M13 phage vector.

Purified double-stranded sequences of DNA (dsDNA) can be labeled intact by the process of nick translation or  
10 random primer extension. The ability of double-stranded probes to hybridize to nucleic acids immobilized within cells is compromised by the ability of the complementary strands to hybridize to each other in solution prior to hybridization with the cellular nucleic acids. Single-  
15 stranded DNA (ssDNA) probes do not suffer this limitation and may be produced by the synthesis of oligonucleotides, by the use of the single-stranded phage M13 or plasmid derivatives of this phage, or by reverse transcription of a purified RNA template. The use of single-stranded RNA  
20 (ssRNA) probes in hybridization reactions potentially provides greater signal-to-noise ratios than the use of either double or single-stranded DNA probes. Regardless of whether a dsDNA, a ssDNA, or a ssRNA probe is used in the hybridization reaction, there must be some means of  
25 detecting hybrid formation. The means of detecting hybrid formation utilizes a probe "labeled" with some type of detectable label.

For a discussion of probes, see *Handbook of Fluorescent Probes and Research Products*, Ninth Edition by  
30 Richard P. Haugland (2002) Molecular Probes.

The probe is labeled with a reporter or ligand or moiety which allows detection of the targeted sequence *in situ*. The probes may be detectably labeled prior to addition to the hybridization solution. Alternatively, a



detectable label may be selected which binds to the reaction product. Probes may be labeled with any detectable group for use in practicing the invention. Such detectable group can be any material having a detectable physical or chemical property. Such detectable labels have been well-developed in the field of immunoassays and in general most any label useful in such methods can be applied to the present invention. Particularly useful are enzymatically active groups, such as enzymes (see Clin. Chem., 22:1243 (1976)), enzyme substrates (see British Pat. Spec. 1,548,741), coenzymes (see U.S. Pat. Nos. 4,230,797 and 4,238,565) and enzyme inhibitors (see U.S. Pat. No. 4,134,792); fluorescers (see Clin. Chem., 25:353 (1979); chromophores; luminescers such as chemiluminescers and bioluminescers (see Clin. Chem., 25:512 (1979)); specifically bindable ligands; proximal interacting pairs; and radioisotopes such as  $^3\text{H}$ ,  $^{35}\text{S}$ ,  $^{32}\text{P}$ ,  $^{125}\text{I}$  and  $^{14}\text{C}$ . For autoradiographic detection, the reporter is a radiolabel, such as  $^{32}\text{P}$ -labeled probe formed, for example by nick translation or polymerase chain reaction in the presence of labeled nucleotides.

For fluorescence detection, the probe may be labeled with one of a selection of fluorescence groups, such as FITC, BODIPY, Texas Red, or Cascade Blue which is excitable in a specific wavelength, such as 490, 540, and 361 nm. The groups are derivatized to 3' or 5' probe ends or by incorporation or reaction at internal positions, according to standard methods.

Alternatively, the probes may be labeled with a ligand-type reporter such as biotin, digoxigenin, or bromodeoxyuridine or other modified bases including fluorescein-11-dUTP. The probe reporter groups are detected, *in situ*, by reaction of the hybridized probe with a secondary reporter molecule which (a) binds specifically and with high affinity to the probe ligands, and (b)

contains a detectable reporter. The binding moiety of the secondary molecule may be avidin or streptavidin, for binding to biotinylated nucleotides, anti-digoxigenin antibody, for binding to digoxigenin-labeled nucleotides, and anti-BrdUrd antibody for binding to BrdUrd-labeled probe.

The detectable reporter in the secondary molecule is typically a fluorescence label, but may also be a radiolabel, for autoradiographic detection, an antibody, an enzyme, for colorimetric or chemiluminescence detection in the presence of a suitable substrate, or colloidal gold for use in electron microscopic visualization.

Nucleic acid hybridization is a process well known in the art where two or more mirror images or opposite strands of DNA, RNA, oligonucleotides, polynucleotides, or any combination thereof recognize one another and bind together through the formation of some form of either spontaneous or induced chemical bond, usually a hydrogen bond. The degree of binding can be controlled based on the types of nucleic acids coming together, and the extent of "correct" binding as defined by normal nucleic acids coming together, and the extent of "correct" binding as defined by normal chemical rules of bonding and pairing.

Hybridization of the probe to the target introduced nucleic acid can be performed using the fixed and permeabilized preparations prepared as described above. If double-stranded target such as chromosomal or DNA sequences are to be detected, a treatment to separate the two strands may be necessary. This separation of the strands can be achieved by heating the sample in the presence of the hybridization mixture to a temperature sufficiently high and for a time period sufficiently long to dissociate the strands. Typically, heating at a temperature of 90°C to 95°C for a period of 5 to 15 minutes is suitable.

The hybridization buffer may contain a hybrid destabilizing agent in an amount effective to decrease the melting temperature of hybrids formed between the nucleic acid to be determined and the binding partner so as to

5 increase the ratio between specific binding and non-specific binding (see US patent 5,888,733). This agent allows the hybridization to take place at a lower temperature than without the agent. In traditional nucleic acid hybridization, such agent is called a denaturing agent.

10 Hybridization and denaturing may be carried out simultaneously using a suitable amount a hybrid destabilizing agent in combination with a suitable temperature for the treatment. Examples of hybrid destabilizing agents are formamide, ethylene glycol and

15 glycerol and these agents may preferably be used in a concentration above 10% and less than 70%. The concentration of formamide may more preferably be from 20% to 60%, most preferably from 30% to 50%. The concentration of ethylene glycol may more preferably be from 30% to 65%, most

20 preferably 65%. The concentration of glycerol may more preferably be from 45% to 60%, most preferably 50%.

It is often advantageous to include macromolecules or polymers such as dextran sulphate, polyvinylpyrrolidone and/or ficoll. In the presence of such macromolecules or

25 polymers, the effective concentration of the probe at the target is assumed to be increased. Dextran sulphate may be added in a concentration of up to 15%. Concentrations of dextran sulphate of from 2.5% to 12.5% may be advantageous.

Other important hybridization parameters are

30 temperature, concentration of the probe and hybridization time. A skilled person will readily recognize that optimal conditions for various starting materials will have to be determined for each of the above-mentioned parameters.

Following hybridization, the prepared biological sample is washed to remove any unbound and any non-specifically bound probes. During the post-hybridization step, appropriate stringency conditions should be used in order to remove any non-specifically bound probe. Stringency refers to the degree to which reaction conditions favour the dissociation of the formed hybrids and may be enhanced, for instance by increasing the washing temperature and incubation time. Salt concentration is often used as an additional factor for regulating the stringency. Examples of useful buffer systems are Tris-Buffered-Saline (TBS), standard citrate buffer (SSC) or phosphate buffers. A convenient TBS buffer is 0.05M Tris/HCl, 0.15M NaCl, pH 7.6. The SSC buffer comprises 0.15M sodium chloride and 0.015M trisodium citrate, pH 7.0. Typically, washing times from 25 to 30 minutes may be suitable. Washing periods of two times 10 minutes or 3 times 5 minutes in a suitable buffer may also be suitable.

Where the preparation is deposited onto slides, the hybridization results may be visualized using well known immunohistochemical staining methods to detect the labelling on the probe. When fluorescent labelled probes are used, the hybrids may be detected using an antibody against the fluorescent label which antibody may be conjugated with an enzyme. The fluorescent label may alternatively be detected directly using a fluorescence microscope, or the results may be automatically analysed on a fluorescent-based image analysis system. The signal may be visualized by confocal microscopy, fluorescence microscopy, or electron microscopy.

When biotin labelled binding partners are used, the hybrids may be detected using an antibody against the biotin label which antibody may be conjugated with an enzyme. If necessary, an enhancement of the signal can be generated using commercially available amplification systems

such as the catalyzed signal amplification system for biotinylated probes (DAKO K 1500).

#### Applications of VOID

VOID is useful for monitoring introduced nucleic acids whenever the nucleic acid is in transit. As examples, a number of specific applications are contemplated below.

Applications of VOID utilize VOID's ability to reveal the number and location of the introduced nucleic acid, as well as its ability to identify the cells that are competent for receiving nucleic acid molecules. In addition, VOID can be used to determine the fate and timing of nucleic acid being delivered into the cells; that is, VOID can be used to identify where the nucleic acid molecules have gone after the nucleic acid has entered the cell and where they are in the cell at any time after cell entry. By the use of VOID, drawbacks associated with current techniques for monitoring nucleic acid delivery and transformation may be avoided.

VOID can be used to help the development of genetically modified products, including gene therapy vectors, gene therapy delivery systems, as well as assess the safety of gene therapy treatments. VOID can also be used to facilitate development of DNA vaccines, DNA vaccine vectors, DNA vaccine delivery systems, and safety assessment of DNA vaccines. In addition, VOID can be used in the development of transgenic or genetic engineered products such as genetically modified food crops.

The use of VOID in genetic modification is significant because for development of safe and effective genetically modified products or gene delivery vectors such as those used in gene therapy, one needs to know the number, location and fate of the nucleic acid delivered into the targeted cells. Because VOID can reveal the number and

location of the nucleic acid delivered into the cells and identify the cell types competent for receiving the nucleic acid, this facilitates identification and development of DNA delivery systems and formulations, and generate efficient nucleic acid delivery where the desired number of nucleic acid molecules are delivered into the desired target cells. Thus use of VOID can considerably speed up the development of genetically modified products including gene therapy products and DNA vaccines.

The use of VOID in the development of transgenic or genetic engineered products is also significant because marker or reporter genes are no longer necessary to monitor nucleic acid delivery and transformation. As a result, transgenic products may be produced that are free of marker or reporter genes which may be of concern for the environment and human health.

VOID can also be used to determine the cell types that can efficiently receive the nucleic acid intended for transformation, thus identifying the best cells and tissues or organs for nucleic acid uptake. As illustrated below with the cellular protein VirD2-Interacting protein (VDI; SEQ ID NO:1), VOID is also useful for identifying molecular markers associated with a cell's competence to receive DNA molecules.

#### I. Assessing transformation status and efficiency

In one embodiment, VOID is used to monitor T-DNA introduced into plant cells by *A. tumefaciens*.

*Agrobacterium tumefaciens* is a natural genetic engineer that transforms plants with its own genes for its own benefits (P. J. Christie. *Mol. Microbiol.* 40:294 (2001); S. B. Gelvin. *Annu. Rev. Plant Physiol. Plant Mol. Biol.* 51:223 (2000); J. Zhu et al. *J. Bacteriol.* 182:3885 (2000); J. Zupan et al. *Plant J.* 23:11 (2000)). The bacterium

transfers a specific segment (T-DNA) of its tumor-inducing (Ti) plasmid into plant cells, where the T-DNA becomes integrated into the plant genome. This system has been used as the workhorse to introduce various genes into many  
5 different plant species.

Recently, it has been demonstrated that *Agrobacterium* can also transfer T-DNA into yeast (Bundock et al. 1995. EMBO J. 14:3206-14; Piers et al. 1996. Proc Natl Acad Sci U S A 93:1613-8), fungal (de Groot MJ et al. 1998. 10 Nat Biotechnol. 16:839-42) and human cells (Kunik et al. 2001. Proc Natl Acad Sci USA. 98:1871-1876). Major bacterial genes involved in the gene transfer process have been identified and characterized (Christie, P. J., 2001. Mol. Microbiol., 40(2), 294-305; Gelvin, S. B., 2000. Annu. 15 Rev. Plant Physiol. Plant Mol. Biol., 51, 223-256; Zhu et al. 2000. J. Bacteriol., 182, 3885-3895; Zupan et al. 2000. Plant J., 23, 11-28).

*A. tumefaciens* genome has been sequenced (Wood, D. W., et al 2001. Science, 294, 2317-2323; Goodner, B., et al 20 2001. Science, 294, 2323-2328). The Ti plasmid harbored virulence (vir) genes are directly responsible for the processing and transfer of T-DNA; all of them are induced by plant signal molecules, such as acetosyringone (AS). VirD2 generates a linear single-stranded (ss) DNA molecule (the T- 25 strand) by nicking the border repeats that delineate the T-DNA (Stachel, S. E., Nester, E. W., 1986. EMBO J., 5, 1445-1454; Yanofsky G, et al. Cell. 1986 Nov 7;47(3):471-7). The T-strand is transferred into plant nuclei presumably in the form of nucleoprotein complex (T-complex) (Ziemienowicz et 30 al. 2001. The Plant Cell, 13, 369-384) consisting of one VirD2 molecule, one T-strand and many VirE2 molecules. The virB gene products and VirD4 form a membrane structure responsible for transferring the T-DNA (Fullner et al. 1996. 273, 1107-1109) in a process mechanistically analogous to

conjugation (Christie, P. J., 2001. Mol. Microbiol., 40(2), 294-305) and promiscuous enough to be applicable to exceptionally diverse recipients like plant, yeast, fungal and human cells.

5           Plant proteins that interact with VirD2 and VirE2 have been identified (Ballas, N., Citovsky, V., 1997. Nuclear localization signal binding protein from *Arabidopsis* mediates nuclear import of *Agrobacterium* VirD2 protein. Proc. Natl. Acad. Sci. USA, 94, 10723-10728; Deng et al. 10 1998. *Agrobacterium* VirD2 protein interacts with plant host cyclophilins. Proc. Natl. Acad. Sci. USA, 95, 7040-7045; Tzfira et al. 2001. VIP1, an *Arabidopsis* protein that interacts with *Agrobacterium* VirE2, is involved in VirE2 nuclear import and *Agrobacterium* infectivity, EMBO J., 20, 15 3596-3607); some plant proteins have been implicated in the nuclear import of T-complex or T-DNA integration (Gelvin, S. B. 2000. Annu. Rev. Plant Physiol. Plant Mol. Biol., 51, 223-256). However, individual T-DNA molecules have never been visualized inside eukaryotic cells during the T-DNA 20 passage *in vivo*.

          It is still unknown how many T-DNA molecules can be delivered into a single eukaryotic cell and how many of them can be transferred from cytoplasm into nucleus. The mode of T-DNA passage into and through eukaryotic cytoplasm 25 remains elusive. It is not well established why some eukaryotes including certain monocotyledonous plants are recalcitrant to *Agrobacterium*-mediated transformation, while many receptive eukaryotes like dicotyledonous plants can be efficiently transformed, with a variable number of 30 integrated T-DNA copies. To help address these questions, VOID was used to monitor T-DNA molecules trafficking inside plant cells. This procedure may be used not only to dissect the T-DNA trafficking pathway(s) inside eukaryotic cells,



but also to monitor the T-DNA transfer and passage inside eukaryotic cells.

Part of a T-DNA fragment was labeled with digoxigenin-11-dUTP (DIG); the T-DNA probe was allowed to permeate the plant cells that had been cocultivated with *A. tumefaciens* cells harboring a vector plasmid (pIG121-Hm) containing the T-DNA (Fig. 1). The T-DNA molecules delivered into the plant cells were allowed to hybridize with the probe DNA labeled with DIG, which could be bound to anti-DIG antibody conjugated with rhodamine which gave red fluorescence when excited by 543 nm light. As shown in Fig 2A, many red dots could indeed be detected under confocal microscope when the tobacco BY2 cells were allowed to cocultivate with LBA4404(pIG121-Hm). The nuclei were counterstained with PicoGreen, which could give green fluorescence, in order to gauge the subcellular locations of T-DNA molecules.

To verify that the red dots indeed corresponded to the T-DNA inside plant cells rather than T-DNA from contaminating *A. tumefaciens*, the following experiments have been conducted. First, the bacteria were extensively washed away after the cocultivation; indeed very few bacteria could be found after the cocultivation and then the VOID procedure. Second, it was determined if the red dots were specifically correlated with the bacterial ability to deliver the T-DNA. The same plasmid pIG121-Hm was introduced into a *virB* mutant MX243 (Stachel & Nester, E. W., 1986. EMBO J., 5, 1445-1454; P. J. Christie. *Mol. Microbiol.* 2001. 40:294), which is unable to deliver the T-DNA, and a *virD2* mutant WR1715 (Stachel & Nester, E. W., 1986. EMBO J., 5, 1445-1454; Shurvinton et al. 1992. *Proc. Natl. Acad. Sci. USA*, 89, 11837-11841; Zupan et al. 2000. *Plant J.*, 23, 11-28), which is unable to produce the T-DNA. When the cocultivation and VOID were conducted with these

mutants, no T-DNA signal was detected inside plant cells (Fig. 2B&C). This indicated that the signal was due to the hybridization of T-DNA with the specific probe.

Finally, it was determined if the signal was due to the untransferred T-DNA still residing inside *A. tumefaciens* cells. The *A. tumefaciens* chromosomal gene *aopB* (Jia Y. H., L. P. Li, Q. M. Hou and S. Q. Pan. 2002. An *Agrobacterium* gene involved in tumorigenesis encodes an outer membrane protein exposed on the bacterial cell surface. *Gene*. 284:113-124) was labelled and the same VOID procedure was carried out. As shown in Fig. 2D, no signal was detectable in the samples when the *aopB* probe was used for hybridization. This indicated that the VOID procedure could not detect any DNA residing inside the bacterial cells, presumably because of insufficient permeabilization of the bacterial membranes. These confirmed that the VOID procedure could detect the T-DNA delivered into plant cells.

## II. Numbers and locations of DNA molecules delivered into cells

Subsequently, it was important to know if the VOID procedure could reveal the location and number of individual T-DNA molecules. To do this, an *Arabidopsis thaliana* cDNA (corresponding to F16N3.18 of the genome sequence) clone was chosen that could hybridize to the BY2 genomic DNA as demonstrated by Southern analysis. When this cDNA fragment was used to probe BY2 cells, VOID consistently revealed 1 or 2 red dots in each single cell nucleus (Fig. 3A&B). No hybridization signal was detected in the cytoplasm of BY2 cells, suggesting that VOID could detect DNA and not RNA molecules as RNase A was added. Conceivably, 2 red dots could be seen if the confocal section in focus contained two nuclear DNA molecules that could specifically hybridize with the cDNA fragment; 1 red dot would be seen if only one was in focus. This indicated that VOID could reveal the

locations and numbers of individual T-DNA molecules present throughout the BY2 cells.

When a *virE2* mutant MX358 (Stachel & Nester. 1986. EMBO J., 5, 1445-1454; Winans et al. 1987. Nucleic Acid  
5 Research 15: 825-836; Zupan et al. 2000. Plant J., 23, 11-28) was used to conduct the cocultivation and VOID procedure, very few T-DNA molecules were found inside the BY2 cells (Fig. 2E). This suggests that mutation at *virE2* may severely attenuate the bacterial ability to deliver the  
10 T-DNA into plant cells, which is consistent with the recent evidence that the VirE2 protein can form a membrane channel to facilitate ssDNA transport (Dumas et al. 2001. Proc. Natl. Acad. Sci. USA, 98, 485-490). It may also indicate that T-DNA molecules were quickly degraded inside plant  
15 cells in the absence of the VirE2 protein, which is known to bind to T-DNA and presumably can protect T-DNA from degradation (Zhu et al. 2000. J. Bacteriol., 182, 3885-3895; Zupan et al. 2000. Plant J., 23, 11-28).

To determine whether DNA segments outside the T-  
20 DNA could also be transferred into the plant cells, a fragment of pIG121-Hm vector backbone outside the left border (Fig. 1) was used to probe the BY2 cells cocultivated with LBA4404(pIG121-Hm). As shown in Fig. 2F, the vector backbone fragment outside the T-DNA were detected in the  
25 plant cells. However, the numbers of such molecules appeared to be about 18 times lower as compared to the T-DNA molecules. This suggests that the binary vector backbone can be transferred into the plant cells along with the T-DNA, although the frequency of such an event is lower than  
30 that for the T-DNA alone. In fact, previous experiments demonstrated that *A. tumefaciens* could transfer DNA sequences outside the T-region and even plasmids into plant cells (Gardner and Knauf. Science, Vol. 231, No. 4739. Feb. 14, 1986, pp. 725-727; Buchanan-Wollaston et al. 1987.

Nature 328: 172-175). These further demonstrated that the VOID procedure could reliably reveal data consistent with the previous observations.

The numbers of T-DNA molecules inside BY2 cells were counted after reconstitution of individual plant cells from sequential 1- $\mu$ m-laser-sections of confocal microscopy. Roughly half of the BY2 cells did not contain any T-DNA molecules, suggesting that the competency of BY2 cells was important for BY2 cells to receive the T-DNA delivered by *A. tumefaciens*. The numbers of T-DNA molecules inside the BY2 cells that had received T-DNA also varied greatly. Some received hundreds of T-DNA molecules (Fig. 2A); some had only a few (Fig. 3C). In a typical cocultivation experiment, the average numbers of T-DNA molecules inside the cytoplasm of a single BY2 cell that received T-DNA were around 63.

### III. Time-course of DNA delivery into cells

BY2 cells were cocultivated with LBA4404 (pIG121-Hm) for different time intervals. As shown in Fig. 4B, the T-DNA was barely detectable in the plant cytoplasm at 2 h of cocultivation, which is consistent with the previous observations that T-DNA could be detected at 2 h after infection of plants with *A. tumefaciens* (Virts & Gelvin. 1985. J. Bacteriol., 162, 1030-8; Narasimhulu et al. 1996. Plant Cell 8: 873-886). Most of the T-DNA molecules entered the plant cytoplasm in 5 h (Fig. 4C). At 1 day of cocultivation, all the T-DNA molecules still remained in the cytoplasm of the BY2 cells (Fig. 4D). At 2 days of cocultivation, all the T-DNA molecules were inside the plant nuclei (Fig. 4E). This is consistent with the  $\beta$ -glucuronidase (GUS) staining experiments, which could indicate the expression of T-DNA. It was found that the GUS activity was not detectable until 2 days of cocultivation (data not shown). These suggest that the T-DNA could enter

plant cells very fast (about 5 h), but it took a longer period (about 2 d) for T-DNA to enter plant nuclei. The T-DNA harbored genes were quickly expressed upon entry of T-DNA into the nuclei.

5 IV. Eliminating need for selection/marker to identify transformant

Widespread use and the subsequent spreading of specific marker genes in genetically modified products has raised concerns about the safety and environmental effects  
10 of these products. Currently genetically modified cells are selected on the basis of expression of a functional product of the DNA delivered; the functional product may be the desired product, or more commonly, the product of a gene that is introduced into the cell along with the gene  
15 encoding the desired product. These latter products are commonly referred to as selection markers or reporters.

Selection markers are those genes which, upon expression, produces a protein capable of facilitating the isolation of cells expressing the marker. Examples of  
20 markers include neomycin, hypoxanthine phosphoribosyl transferase, puromycin, dihydroorotase, glutamine synthetase, histidine D, carbamyl phosphate synthase, dihydrofolate reductase, multidrug resistance I, aspartate transcarbamylase, xanthine-guanine phosphoribosyl  
25 transferase, or adenosine deaminase. In plants, markers are used that confer on the transformed plant cells resistance to a biocide or an antibiotic, such as kanamycin, G 418, bleomycin, hygromycin, or chloramphenicol, etc.

Reporter genes encode a functional product such  
30 that when the gene is expressed, the product is detectable by means of a suitable assay. Common reporter genes include genes encoding luciferase, beta-galactosidase,

chloramphenicol acetyl transferase, secreted alkaline phosphatase or Green Fluorescent Protein (GFP) gene.

Since the function of the selection marker or reporter is to permit identification and selection of the transformed cell, the marker or reporter becomes unnecessary after the transformant is identified. Thus ideally the transformed cell would contain only the desired nucleic acid, with as little as possible of non-essential material, such as marker genes and remnants of the DNA used for cloning.

In one embodiment, VOID is used to identify cells that contain the T-DNA introduced into plant cells by *A. tumefaciens*. Identification of transformed cells is determined by monitoring entry of the T-DNA into the nucleus. As shown in Figure 4C, most of the T-DNA molecules entered the cytoplasm in 5 h. However, none of them entered the nucleus even at 1 day of cocultivation (Fig. 4D). Once they entered the nucleus in 2 days, no T-DNA molecule could be found in the cytoplasm (Fig. 4E). These results indicate that the T-DNA molecules appeared to have moved into the nucleus together in one wave. The data also suggest that the T-DNA trafficking inside plant cells is not a simple diffusion process. If it was a diffusion process, some T-DNA molecules would have arrived inside the nuclei at 1 day of cocultivation, since many T-DNA molecules were already present throughout the cytoplasm at 5 h of co-cultivation. In addition, some of them would have remained inside the cytoplasm while others entered the nucleus.

Previous experiments with an *in vitro* nuclear import system demonstrated that T-complex could be translocated from plant cytoplasm into nucleus very quickly (within 20 min) (Ziemienowicz et al. 2001. The Plant Cell, 13, 369-384). The *in vivo* data indicated that T-DNA trafficking inside plant cytoplasm was very slow. It

appeared that the T-DNA molecules inside cytoplasm were somehow unavailable for or prohibited from the quick nuclear import process. Consistent with this, T-DNA trafficking inside plant cytoplasm appeared to occur in a coordinated manner, as only one wave of T-DNA trafficking was apparent during the 3-day cocultivation (Fig. 4).

Thus by using VOID, the cycle of T-DNA import into the nucleus is observed, and cells which have undergone T-DNA import can be identified without having to use a selection or marker product.

#### V. Assessing risk associated with transformation or nucleic acid delivery

It is important to know how many DNA molecules have been delivered into the cells and where the molecules have gone. This is because an excess number of DNA molecules delivered into the cells could potentially lead to unwanted integration of some of the DNA molecules into vital sites of the genome, which could lead to serious health problems to the host. Since VOID can be used to determine the number and location of the nucleic acid delivered into the cells, VOID can be used to calculate the risk associated with a genetically modified product transformed using a particular gene delivery process.

By monitoring the fate of the exogenous nucleic acid in the cell, one can assess the relative safety not only of a particular gene delivery technique, but also the risk associated with using a particular nucleic acid delivery vehicle. For example, the uptake, number, location, and movement of a desired gene may be monitored when the gene is delivered as part of a naked plasmid, as part of a liposomal complex, as part of a viral delivery system such as retroviral vectors, adeno associated viral vectors, herpes simplex viral vectors, and bacteriophage

vectors; as part of a nucleic acid associated with cationic peptides, or as part of an *Agrobacterium tumefaciens* vector. Depending on the context in which the desired gene is delivered, the desired gene may be stable or unstable in the cell; the gene may also be capable of replicating at different rates and efficiency. All these factors are important in assessing the desirability of using a particular gene delivery system.

In one embodiment, VOID is used to assess the risk associated with *A. tumefaciens*-mediated transformation of plant cells. The efficiency of T-DNA molecules that moved from cytoplasm into nucleus was assessed by determining the ratio of the numbers of T-DNA molecules inside cytoplasm to those inside nucleus. In a typical cocultivation, it was found that 1 in 6 T-DNA molecules moved from cytoplasm to nucleus (Fig. 4D&E). This demonstrated that not every T-DNA molecule delivered into plant cytoplasm could make all the way into the nucleus, suggesting that the transformation process involved a shot-gun approach. Since the VOID procedure could reveal the number and location of T-DNA molecules trafficking inside plant cells, VOID is useful for calculating risks associated with certain transformation or DNA delivery processes.

Since 1 out of 6 T-DNA molecules moved from the cytoplasm into the nucleus, 6 T-DNA molecules would be the minimal number of DNA molecules that need to be delivered into the cytoplasm per cell in order to generate a transgenic plant containing one copy of the transgene in the plant genome. If 60 T-DNA molecules were delivered into cytoplasm per cell, the risk of generating a transgenic plant containing multiple copies of the transgene would increase 10 fold. Similarly, the risk of generating a transgenic plant containing the transgene inserted at an undesired site would also increase 10 fold. If there were



600 T-DNA molecules delivered into cytoplasm per cell, the risk of generating an undesired transgenic product would increase 100 fold, although the transformation efficiency would also increase. One must compromise between transformation efficiency and the risk of an undesired outcome. The VOID procedure can facilitate the determination of an appropriate compromise in the early stage of product development.

The risk associated with a particular gene delivery vehicle such as a gene therapy vector or a DNA vaccine vector may be assessed in a similar fashion. For example, a gene therapy vector may be used to treat a test subject. The number and location of the nucleic acid molecules inside the treated cells may be determined as described above, at various time intervals after the treatment. The ratio of the nucleic acid molecules present in the cytoplasm to those in the nucleus can be calculated. The risk associated with the treatment can be then assessed as described above.

#### VI. Controlling the copy number of nucleic acid molecules delivered

During the development of a transgenic product or gene delivery vehicle, it is important to control the copy number of nucleic acid molecules delivered into target cells. In some circumstances, a high copy number of the nucleic acid molecules may be desired in order to have a high expression level of products encoded by the nucleic acid. In other circumstances, only one copy of the nucleic acid molecule may be desired per target cell. Since VOID can reveal the number and location of nucleic acid molecules delivered during the early stage of development, VOID may be used to control the copy number of the nucleic acid molecules. This may be achieved by manipulating the parameters associated with the nucleic acid delivery, for

instances, methods of nucleic acid delivery, timing, length of time and conditions of the delivery, and conditions (and types) of target cells.

In one embodiment, the number of T-DNA molecules delivered by *Agrobacterium* could be controlled by the length of time for co-cultivation. BY2 cells were cocultivated with LBA4404 (pIG121-Hm) for different time intervals. As shown in Fig. 4B, the T-DNA was barely detectable in the plant cytoplasm at 2 h of cocultivation, which is consistent with previous observations that T-DNA could be detected at 2 h after infection of plants with *A. tumefaciens* (Virts & Gelvin. 1985. J. Bacteriol., 162, 1030-8; Narasimhulu et al. 1996. Plant Cell 8: 873-886). Most of the T-DNA molecules entered the plant cytoplasm in 5 h (Fig. 4C). At 1 day of cocultivation, all the T-DNA molecules still remained in the cytoplasm of the BY2 cells (Fig. 4D). At 2 days of cocultivation, all the T-DNA molecules were inside the plant nuclei (Fig. 4E). This demonstrates that the number of T-DNA molecules delivered into cytoplasm can be controlled by choosing the appropriate length of time for co-cultivation. Thus an appropriate copy number of the transgene in the target cell can be achieved.

In another embodiment, the number of T-DNA molecules delivered by *Agrobacterium* could be controlled by the use of different bacterial strains to deliver the T-DNA molecules. When a *virE2* mutant MX358 (Stachel & Nester. 1986. EMBO J., 5, 1445-1454; Winans et al. 1987. Nucleic Acid Research 15: 825-836; Zupan et al. 2000. Plant J., 23, 11-28) was used to conduct the cocultivation and VOID procedure, very few T-DNA molecules were found inside the BY2 cells (Fig. 2E). By contrast, when a wild-type *Agrobacterium* strain was used, some plant cells received hundreds of T-DNA molecules (Fig. 2A). This suggests that mutation at *virE2* may severely attenuate the bacterial

ability to deliver the T-DNA into plant cells and demonstrates that DNA delivery depends in part on the bacterial strains used.

The finding that *vire2* can attenuate T-DNA delivery is consistent with the recent evidence that the VirE2 protein can form a membrane channel to facilitate ssDNA transport (Dumas et al. 2001. Proc. Natl. Acad. Sci. USA, 98, 485-490). It may also indicate that T-DNA molecules were quickly degraded inside plant cells in the absence of the VirE2 protein, since VirE2 is known to bind to T-DNA and presumably can protect T-DNA from degradation (Zhu et al. 2000. J. Bacteriol., 182, 3885-3895; Zupan et al. 2000. Plant J., 23, 11-28).

While some plant cells received hundreds of T-DNA molecules when a wild-type *Agrobacterium* strain was used (Fig. 2A), some receive only a few T-DNA (Fig. 3C). In a typical cocultivation experiment, the average numbers of T-DNA molecules inside the cytoplasm of a single BY2 cell that received T-DNA were around 63. This demonstrates that DNA delivery depends not only on the bacterial strains, but also on the target cells. In one embodiment, particular strains of *Agrobacterium* may be selected for a particular target cell population so that an appropriate number of the transgene is delivered into the cells.

VII. Screening for molecular markers associated with transformation and identifying VDI and Sec3 homologs as molecular markers

In the context of this invention, molecular markers are proteins which are required for, or assist in, the delivery of introduced DNA into the nucleus; thus molecular markers identify cells which are competent to receive exogenous nucleic acid.

In identifying molecular markers associated with transformation competency, cells into which an exogenous nucleic acid has been introduced are monitored with VOID. The cells are further assayed for co-localization of a cellular protein with the exogenous nucleic acid to determine whether the cellular protein is consistently in close proximity to the exogenous nucleic acid. Co-localization would indicate that the cellular protein is a molecular marker associated with competency to receive exogenous nucleic acid.

In one embodiment, the cellular protein and its location in the cell are identified by immunohistology, using an antibody which binds specifically to the cellular protein. The antibody must be able to bind to the cellular protein (the antigen) in the fixed cell; usually, but not always, this means the antibody must be able to bind to the denatured form of the cellular protein.

In the context of this invention, the cellular protein is any protein which is located in the cytoplasm, the cytosol, the plasma membrane, or the nuclear membrane. Preferably the protein has a surface-exposed or cytoplasm-exposed domain if the protein is located in the plasma membrane. Preferably the protein has a cytoplasm-exposed domain if the protein is located in the nuclear membrane.

In a preferred embodiment, the cellular proteins to be screened as a molecular marker are those which interact with VirD2 or VirE2 (Gelvin. 2000. Annu. Rev. Plant Physiol. Plant Mol. Biol., 51, 223-256). In another embodiment, the cellular protein is VIP1 (Tzfira et al. 2001. EMBO J., 20, 3596-3607), cyclophilins (Deng et al. 1998. Proc. Natl. Acad. Sci. USA, 95, 7040-7045), including specifically cyclophilins having Genbank accession numbers L14844, L14845 and U07276, AtKAP (Ballas, N., Citovsky, V. 1997. Proc. Natl. Acad. Sci. USA, 94, 10723-10728), and

homologs of Sec3, including human, *Drosophila*, rat, mouse and *Caenorhabditis elegans* Sec3 (human exocyst component Sec3 Accession number Q9NV70 and homolog accession number NP\_060731.1; *Drosophila* accession number Q9VVG4; rat  
5 accession number XP\_223340.1 and XP\_223339.1; mouse accession number AAH24678.1; *Caenorhabditis elegans* accession number NP\_508530.1). In another embodiment, the cellular protein is a protein of the Exocyst complex.

Immunohistology is performed according to methods  
10 known in the art (see for example US patent 5,869,274). In one method, a target antigen present in the sample is detected by a double antibody system. Initially the sample is incubated with a primary targeting antibody that is specific for the target antigen. Detection of antigen-  
15 antibody complexes containing the primary antibody and formed during the first incubation is accomplished by incubation with a second detecting antibody that binds to a region of the constant domain in the primary antibody; the second antibody is labeled. The result of the second  
20 incubation is, in the presence of the target antigen, a complex of antigen and layers of antibodies that contain the label.

In one embodiment, VOID is used to identify molecular markers associated with *A. tumefaciens*-mediated  
25 transformation of plant cells.

BY2 cells that had undergone co-cultivation with *A. tumefaciens* appear to be clustered in groups which either could, or could not, receive T-DNA. Roughly half of the BY2 cells did not contain any T-DNA molecules, suggesting that  
30 the competency of BY2 cells was important for BY2 cells to receive the T-DNA delivered by *A. tumefaciens*. When the cells received the T-DNA, often all the cells in the same cluster received T-DNA; otherwise, none of the cells in the same cluster received any T-DNA. The BY2 cells were

undifferentiated; perhaps, the cell cycle stage may account for the competency to receive T-DNA. VOID could thus facilitate investigations on the plant cell competency to receive T-DNA.

5           In order to screen for plant proteins that may be important for receiving T-DNA molecules, the plant protein VDI (SEQ ID NO:1) that interacts with *A. tumefaciens* guide protein VirD2 was investigated as a candidate molecular marker by studying its position inside plant cells during T-DNA delivery. To localize VDI in *A. thaliana* and tobacco BY2 cells, immunohistology was conducted with anti-VDI as the primary antibody and anti-rabbit IgG-conjugated with Cy3 as the secondary antibody. As shown in Fig. 5, VDI was localized in the cytoplasm of BY2 (Fig. 5A) and *A. thaliana* cells (Fig. 5B), whereas no signal was detected in the control when preimmune serum instead of anti-VDI was used (Fig. 5C).

Surprisingly, VDI was not expressed uniformly in all the plant cells. Some cells produced much more VDI than others; many cells did not produce a detectable level of VDI proteins (Fig. 5). The BY2 cells were undifferentiated; it is possible that the cell cycle stage may account for this phenomenon, as the individual cells are undergoing different stages in cell cycling. This uneven expression of VDI in plant cells may explain why only certain cells rather than all BY2 cells could be transformed by *A. tumefaciens* (Fig. 6). In addition, this might be related to why a high transformation efficiency is normally associated with freshly subcultured BY2 cells. Perhaps only these freshly divided cells are competent to receive the T-DNA.

Double immunohistological staining of VDI and -glucuronidase (GUS) was conducted for *Agrobacterium*-transformed BY2 cells, using anti-VDI or anti-GUS as the primary antibody and anti-rabbit IgG conjugated-Cy3 or anti-

mouse IgG conjugated-FITC as the secondary antibody. The samples were prepared after cocultivation of BY2 cells and preinduced *A. tumefaciens* for 3 days.

As shown in Fig. 7, the VDI (red dots) and  
5 reporter marker -glucuronidase (GUS) (green dots) coexisted in the same transformed cells. The BY2 cells producing VDI also expressed the GUS protein encoded on the T-DNA delivered from *Agrobacterium*. In contrast, the remaining cells that lacked the VDI protein also did not produce any  
10 detectable -glucuronidase protein. This suggests that VDI is associated with *Agrobacterium*-mediated transformation of plants.

It is likely that only cells in a certain stage of the cell cycle can produce VDI and consequently are  
15 competent to receive T-DNA and transformed by *Agrobacterium*. Cells in other stage(s) could not produce VDI and consequently are not competent to receive T-DNA. This is consistent with the observation that roughly half of undifferentiated plant cells did not take up any T-DNA.

20 Coexistence of VDI with T-DNA was observed in transformed BY2 cells. The samples were prepared after coincubation of BY2 cells and preinduced LBA4404 (pIG121-Hm) for 1 day. They were then subjected to the VOID procedure to observe T-DNA, and immunohistology to localize VDI. The  
25 VOID procedure was performed with the same fragment of the GUS gene as the probe, which was labeled with the Biotin High Prime kit; anti-Avidin was used as the antibody to detect the T-DNA molecules (green dots in Fig. 8). Immunohistology was performed with anti-VDI and anti-rabbit  
30 IgG conjugated with Cy3 as the primary and secondary antibody, respectively.

As shown in Fig. 8, T-DNA molecules (green dots) appeared to coexist with VDI (red dots) together in the

plant cells transformed by *A. tumefaciens*. In contrast, no T-DNA molecules were detectable in the cells that did not produce VDI. This demonstrates that VDI played an important role in the *Agrobacterium*-mediated plant transformation.

5           It was observed that VDI and T-DNA molecules were quite close to each other (Fig. 8); this suggests that VDI may assist trafficking of the T-complex in the plant cytoplasm. As shown in Figs. 5, 7 and 8, VDI protein appeared to be randomly distributed in the cytoplasm of  
10 untransformed BY2 cells, while VDI was clustered with T-DNA in the transformed BY2 cells at 1 day of cocultivation. After cocultivation for 3 days, VDI protein became randomly distributed in the cytoplasm of plant cells like the untransformed cells. In the control experiment, VDI was  
15 still randomly distributed in the cytoplasm of BY2 cells, which were cocultivated with MX243 (*virB* mutant strain) that is unable to deliver T-DNA (Stachel, S. E., Nester, E. W. 1986. The genetic and transcriptional organization of the *vir* region of the A6 Ti plasmid of *Agrobacterium*  
20 *tumefaciens*. EMBO J., 5, 1445-1454) (Fig. 7B and Fig. 8B). These results clearly demonstrate that VDI actually participated in the process of *Agrobacterium*-mediated plant transformation.

          The results described above indicate that VDI can  
25 be used as a molecular marker for cell competency to receive T-DNA. Thus identification of VDI in a cell indicates that the cell is transformation competent. Expression of cellular VDI can be determined using known methods in the art, including immuno detection with anti-VDI antibodies,  
30 such as Western blotting and ELISA, and immunoprecipitation of metabolically labeled cells using anti-VDI antibodies.

          The plant VDI protein is homologous to the human Sec3 throughout the entire length of the proteins (see Figure 9 for a comparison of VDI with a number of exemplary



Sec3 sequences). This indicates that VDI is an ortholog of the human Sec3 protein. The Sec3 homologs are well conserved in eukaryotic cells. It is thus contemplated that homologs of Sec3, apart from VDI, also are useful as

5 molecular markers for cell competency to receive exogenous nucleic acid. Examples of Sec3 homologs include human Sec3 (Accession number Q9NV70 and NP\_060731.1), Drosophila Sec3 (Accession number Q9VVG4), rat Sec3 (Accession number XP\_223340.1 and XP\_223339.1), mouse Sec3 (Accession number

10 AAH24678.1), and Caenorhabditis elegans Sec3 (Accession number NP\_508530.1).

Sec3 is a component of the Exocyst complex, which is well conserved in eukaryotic cells. Yeast and human Exocyst complexes have been identified (Matern et al. Proc

15 Natl Acad Sci USA 2001 Aug 14;98(17):9648-53). These Exocyst complexes exist as protein complexes consisting of several protein components. Since components of the Exocyst complex co-localize with Sec3 protein (Matern et al. Proc Natl Acad Sci USA 2001 Aug 14;98(17):9648-53), it is

20 contemplated that other components of the Exocyst complexes may also be used as molecular markers of a cell's competency to receive exogenous nucleic acid.

#### VIII. Identifying, characterizing and producing cells competent to receive exogenous nucleic acid

25 It is contemplated that fusions of Sec3, including VDI, with Green Fluorescent Protein (GFP), is useful to identify, characterize and produce cells competent to receive exogenous nucleic acid. It is further contemplated that regulated expression of exogenous Sec3 will produce

30 cells more competent to receive exogenous nucleic acid.

Since the Sec3 homolog VDI is correlated with transformation competence, competent cells can be selected if one is able to select for cells expressing Sec3 without

5 killing the cells in the process. Methods for selecting cells expressing a particular protein are known in the art. For example, Sec3 protein may be fused in frame with GFP or its variants, and the fusion protein stably expressed in the cell under the control of the native Sec3 promoter. Stable transformants expressing Sec3-GFP can be directly isolated by fluorescence activated cell sorting (FACS) using appropriate excitation wavelengths and emission detector. Techniques for making the fusion constructs, stably introducing the constructs into cells, and isolating and characterizing cells are routinely practised in the art. In fact, a Sec3 homolog has been fused with GFP; the fusion protein has been expressed and correctly localized in the cells (Matern et al. Proc Natl Acad Sci USA 2001 Aug 14;98(17):9648-53).

20 A variety of GFP mutants are available which have distinct spectral properties, improved brightness and enhanced expression and folding in mammalian cells compared to the native GFP (Green Fluorescent Proteins, Chapter 2, pages 19 to 47, edited Sullivan and Kay, Academic Press, U.S. Pat. No. 5,625,048, U.S. Pat. No. 5,777,079, and U.S. Pat. No. 5,804,387).

25 It is further contemplated that expression of Sec3 in cells that do not express endogenous Sec3 will enhance the cell's competence to receive exogenous nucleic acid. As an example, Sec3 may be provided to a cell by way of an expression vector. The level of Sec3 may be regulated by placing the gene encoding Sec3 under control of high expression eukaryotic promoter/enhancers such as the CMV promoter/enhancer, SV40 promoter/enhancer, RSV LTR, herpes simplex thymidine kinase promoter. In a preferred embodiment, inducible promoters may be used to drive expression of Sec3 so that Sec3 expression can be turned on

only when required, i.e. when nucleic acid delivery is carried out.

Inducible promoters contain transcription regulatory regions that function to transcribe mRNA only when inducing conditions are present. Examples of suitable inducible promoters include the *E. coli* lac operator responsive to IPTG, the metallothionein promoter metal-regulatory-elements responsive to heavy-metal (e.g. zinc) induction, the phage T7 lac promoter responsive to IPTG, the various heat-shock promoters, the mouse mammary tumor virus (MMTV) steroid-inducible promoter, the synthetic GAL4-VP16 inducible system, Stratagene's LacSwitch™ inducible mammalian expression system, glucocorticoid response element containing promoter, and the ectdysone promoter (US patent 6,333,318).

#### **EXAMPLES**

##### *Agrobacterium*-mediated transformation

Tobacco (*Nicotiana tabacum*) BY2 suspension-cultured cells were maintained in Murashige and Skoog (MS) liquid medium (Murashige, T., and Skoog, F. 1962. *Physiol Plant* 15: 473-497) supplemented with 0.2 mg/L of 2,4-D; the cultures were incubated at RT with shaking at 100 rpm and subcultured every week with a 4% inoculum. *A. tumefaciens* was grown overnight on AB medium; the cells were collected and then resuspended in IB medium (Cangelosi et al. 1991. *Methods Enzymol.*, 204, 384-97) supplemented with 100  $\mu$ M acetosyringone (AS). The cells were incubated at 28°C for 16-18 hr. After washing with MS medium, 100  $\mu$ l of the bacterial cell suspension ( $5 \times 10^8$  cells/ml) was added to 4 ml of BY2 cell suspension that was 3 days old after the weekly subculturing. After incubation at RT for a certain time interval, the bacterial cells were washed away from the plant cells as described previously (Lee et al. 1999. J.

Bacteriol. 181(1):186-196). The plant cells were then subjected to the GUS assay or VOID.

VOID monitoring of T-DNA in transit

BY2 cells were subjected to the following VOID  
5 procedure after *A. tumefaciens* had transferred T-DNA into  
the BY2 cells. The cells were fixed in 2% paraformaldehyde  
for 2 h and then were washed for 3 times with a freshly  
prepared fixative solution (ethanol mixed with glacial  
acetic acid at a ratio of 3:1). They were kept in the  
10 fixative solution at -20°C until use.

The fixed cells were transferred to clean slides;  
the slides were allowed to air-dry for 1-2 days at RT.  
Immediately before *in situ* hybridization, the fixed cells on  
the slides were incubated in 0.2 % cellulase (in 0.01 M  
15 citrate buffer, pH 4.8) for 30 min at 37°C. After washing  
for 3 times in 0.01 M citrate buffer for 10 min, the cells  
were permeabilized with 0.2% Triton X-100 in PBS buffer for  
10 min at 4°C. The cells were then washed for 3 times in  
PBS buffer for 10 min; they were treated with 100 g/ml of  
20 RNase A in 2 x SSC for 60 min at 37°C.

After washing 3 times in 2 x SSC for 5 min, the  
slides were dehydrated in a 70%, 90% and 100% ethanol  
series. After denaturation in hybridization oven at 80 °C  
for 10 min, each slide was incubated with 20 l of the  
25 hybridization mixture that had been heated at 75°C for 10  
min and then chilled on ice for 10 min. The hybridization  
mixture contained 50% deionized formamide, 10% dextran  
sulfate, 2 x SSC, 0.01% salmon sperm DNA and 10 ng/ l of a  
DNA probe that had been labeled with digoxigenin-11-dUTP  
30 (DIG) using the DIG High Prime kit (Roche Diagnostics) with  
random primers and denatured at 95°C for 10 min and chilled  
on ice for 10 min. The slides were then covered with a

clean coverslip and incubated overnight at 37°C in a humid chamber.

After the coverslips were removed, the slides were washed twice in a solution containing 50% formamide and 2 x SSC for 15 min at 37°C, washed once at 37°C in 2 x SSC for 15 min, and then washed once at RT in 2 x SSC for 15 min, and finally washed once at RT for 5 min with PBS buffer. The slides were incubated in a blocking solution (3% BSA in PBS buffer) at 37°C for 1 hr. To each slide was added 100  $\mu$ l of rhodamine-conjugated anti-DIG antibody (Roche Diagnostics) diluted (1:200) in the blocking solution. The slide was covered with a coverslip and incubated in a humid chamber at 37°C for 45 min. After washing 4 times with 2 x SSC containing 0.1% Tween-20 for 10 min, the slides were then dehydrated with a 70%, 90% and 100% ethanol series. The slides were finally air-dried and mounted with Vectashield mounting medium (Vector laboratories) containing PicoGreen (Molecular Probes) that can counterstain the nuclei of BY2 cells.

The slides were examined with an Olympus Fluoview 300 confocal microscope system. The excitation light for the green and red signal was 488 nm and 543 nm, respectively. The emission for the green and red signal was 515-560 nm bandpass filter and 565 nm longpass filter, respectively. The images for the green and red signals were overlapped in a computer by using the software provided by Olympus.

#### Use of VOID to identify molecular markers associated with transformation

To determine the subcellular location of a plant protein VDI (which interacts with *Agrobacterium* protein VirD2), the plant cells were fixed in 2% paraformaldehyde in 1 x PBS/pH 7.4 for 3 hrs at room temperature. After cells

were affixed to slides pre-coated with poly-L-lysine (Sigma), the slides were washed 3 times in 1 x PBS for 10 min. After the cells were digested with 0.2% cellulase in 0.01 M citrate buffer (pH 4.8) for 30 min at 37 °C, they were  
5 permeabilized in 0.2% Triton X-100 (in PBS) for 5 min at 4°C. The cells were washed 3 times in PBS for 10 min and blocked in PBS containing 3% BSA for 1 hr. To each slide, 100  $\mu$ l of primary antibody (anti-VDI) (diluted 1:100 into the blocking solution) was then added. The slides were covered with a  
10 coverslip and incubated for 1 hr at RT in a humid chamber. After being washed 3 times with PBS containing 3% BSA for 10 min, the slides were incubated in 100  $\mu$ l of secondary antibody (FITC or CY3 conjugated) at a dilution of 1:100 with a coverslip for 1 hr in a humid chamber at RT. The  
15 slides were washed 3 times in PBS containing 0.1% Tween-20 for 10 min, then blown dry and mounted with a drop of Vectashield mounting medium (Vector Inc) with the coverslip sealed with clear nail polish to prevent drying and movement under the microscope. In some cases, the mounting medium  
20 was supplemented with PicoGreen (Molecular probes Inc) that can counterstain the nuclei of plant cells.

The foregoing is considered as illustrative only of the principles of the invention. Since numerous modifications and changes will readily occur to those  
25 skilled in the art, it is not desired to limit the invention to the exact modes of operation shown and described. Accordingly, all suitable modifications and equivalents may be resorted to, falling within the scope of the invention.

**I CLAIM:**

1. A process for monitoring exogenous nucleic acid in transit, the nucleic acid having been introduced into a cell, the process comprising:
  - 5 (a) providing a biological sample containing cells into which exogenous nucleic acid has been introduced, wherein the exogenous nucleic acid is in transit;
  - (b) fixing the cells; and
  - (c) subjecting the cells to an *in situ* hybridization  
10 procedure which comprises contacting the permeabilized cells with a probe which hybridizes to the exogenous nucleic acid; and
  - (d) visualizing the exogenous nucleic acid in transit.
2. The process according to claim 1 for determining  
15 the number of exogenous nucleic acid in the cytoplasm or in the nucleus.
3. The process according to claim 1 for determining whether the exogenous nucleic acid is in the cytoplasm or the nucleus.
- 20 4. The process according to claim 1 for determining the length of time required for the exogenous nucleic acid to appear in the cytoplasm.
5. The process according to claim 1 for determining the length of time required for the exogenous nucleic acid  
25 to appear from the cytoplasm to the nucleus.
6. The process according to claim 1 for determining the efficiency of delivery of the nucleic acid into the nucleus, the process further comprising the step of measuring the ratio of the number of the exogenous nucleic

acid in the nucleus to the number of the exogenous nucleic acid in the cytoplasm.

7. The process according to claim 1 for assessing risk associated with introduction of the exogenous nucleic acid into the cell, the process further comprising the step of determining the number of exogenous nucleic acid in the cytoplasm and in the nucleus at different time intervals after the exogenous nucleic acid has been introduced; determining the ratio of exogenous nucleic acid in the nucleus to cytoplasm at each interval; and predicting, in accordance with said ratio and number of exogenous nucleic acid introduced, the risk associated with introduction of the exogenous nucleic acid into the cell.

8. A process for determining the optimum parameters for obtaining a desired copy number of exogenous nucleic acid introduced into the cell, the process comprising:

(a) introducing an exogenous nucleic acid into a cell under a set of parameters;

(b) monitoring the exogenous nucleic acid according to the process defined in claim 1 to determine the number of exogenous nucleic acid in the cytoplasm or in the nucleus at different time intervals after the nucleic acid has been introduced; and

(c) determining the set of parameters under which the exogenous nucleic acid is delivered in the desired copy number into the cell.

9. The process according to claim 8 wherein one of the parameters is the length of time in which the exogenous nucleic acid is in contact with the cell.



10. The process according to claim 8 wherein one of the parameters is the ability of a gene delivery vector to deliver the exogenous nucleic acid.

11. A process for determining the proportion of cells  
5 competent to receive exogenous nucleic acid, the process comprising:

(a) introducing an exogenous nucleic acid to a portion of a population of cells;

(b) monitoring the exogenous nucleic acid according to  
10 the process defined in claim 1 to determine the presence of the exogenous nucleic acid in the cell; and

(c) determining the number of cells in which the exogenous nucleic acid is present as a proportion of the portion of cells, wherein the proportion is the proportion  
15 of cells of the population competent to receive the exogenous nucleic acid.

12. A process for identifying whether a cell contains an exogenous nucleic acid, wherein the exogenous nucleic acid is free of sequences encoding a selection marker or  
20 reporter protein intended to select for or identify the cell as containing the exogenous nucleic acid, the process comprising:

(a) introducing the exogenous nucleic acid into the cell; and

25 (b) monitoring the exogenous nucleic acid according to the process defined in claim 1;

wherein visualization of the nucleic acid in the cell indicates that the cell contains the exogenous nucleic acid.

13. A process for identifying a molecular marker  
30 associated with the competency of a cell to receive

exogenous nucleic acid, wherein the cell comprises an antigen, the process comprising:

- (a) introducing an exogenous nucleic acid to the cell;
- (b) monitoring the exogenous nucleic acid according to  
5 the process defined in claim 1;
- (c) testing the fixed cells for binding of the antigen with an antibody, wherein the antibody is capable of binding to the antigen in the fixed and permeabilized cell; and
- (d) determining whether the antigen co-localizes with  
10 the exogenous nucleic acid in transit;

wherein co-localization of the exogenous nucleic acid in transit with the antigen indicates that the antigen is a molecular marker associated with transformation competency.

14. A process for identifying a cell that is competent  
15 for receiving exogenous nucleic acid, the process comprising monitoring the exogenous nucleic acid according to the process defined in claim 1 for presence of the exogenous nucleic acid in the cell.

15. The process according to any one of claims 1 to 14  
20 wherein the nucleic acid is DNA.

16. The process according to claim 15 wherein the DNA is introduced into the cell by *Agrobacterium*.

17. The process according to any one of claims 1 to 16 wherein the *in situ* hybridization procedure is fluorescence  
25 *in situ* hybridization.

18. The process according to any one of claims 1 to 17 wherein the cell is a plant cell.

19. The process according to claim 18 further comprising the step of removing the cell wall.

20. The process according to any one of claims 1 to 19, further comprising the step of permeabilizing the cells prior to contacting the cells with the probe.

21. A process for identifying a cell competent to receive exogenous nucleic acid, the process comprising the step of identifying expression of a Sec3 protein in the cell, wherein Sec3 expression indicates that the cell is competent to receive exogenous nucleic acid.

22. The process according to claim 21, wherein the Sec3 protein is VirD2-Interacting protein (VDI), and wherein the cell is a plant cell.

23. A process for identifying a cell competent to receive exogenous nucleic acid, comprising the step of identifying expression of a component of Exocyst complex in the cell, wherein expression of the component indicates that the cell is competent to receive exogenous nucleic acid.

24. The process according to 21 or 23 wherein the cell is a plant cell.

25. A kit for monitoring exogenous nucleic acid in transit, the nucleic acid having been introduced into a cell, the kit comprising:

(a) reagents for fixing the cells;

(b) reagents for permeabilizing the fixed cells;

(c) reagents for *in situ* hybridization of a probe with the exogenous nucleic acid; and

(d) instructions for using the reagents (a) to (c) to monitor the exogenous nucleic acid in transit.


26. A process for producing cells competent to receive exogenous nucleic acid, the process comprising the step of

expressing Sec3 protein under control of an inducible promoter in the cell.

27. The process according to claim 26, wherein the Sec3 protein is VirD2-Interacting protein (VDI), and wherein  
5 the cell is a plant cell.


1/12

Fig. 1



BEST AVAILABLE COPY

**Fig. 2**





**Fig. 3**


Fig. 4






5/12

**Fig. 5**




**Fig. 6**




7/12

Fig. 7



8/12

**Fig. 8**



9/12

**FIG. 9: VDI sequence (top) vs Sec3 Homologs (bottom)**

Q9NV70 Human Exocyst complex component Sec3 (BM-012) Length = 894

5 Query: 55 LALSVKSKGPRKKAFLRVMKYSSGGVLEPAKMYKLKHLKSKVEVITNDPSGCTFTLGFDNL 114  
L +V ++ P + ++V K G + + L+ L+ V+ F L F+ +  
Sbjct: 38 LCATVTTERPVQVKVVKVKKSDKGDYKQIAWALRD LAVVDAKDAIKENPEFDLHFEKI 97

10 Query: 115 RSQSVAPPQWTRNTDDRNRLLCILNICKDVLGRLPKVVGIDIVEMALWAKDNTPVVTT 174  
+W +T ++N + CI + + L + ID V N  
Sbjct: 98 Y-----KWVASSTA EKNAFISCIWKLNQRYLRK-----KIDFV-----NVSSQLL 137

15 Query: 175 QRSTEDGEPAESVTESDLKVTVEKELVSQAEEEDMEALLGTYVMGIGEAFAFSERLKRE 234  
+ S GE +SVT D +V E + ++ EE+D+E ++ I AEAF+E+L RE  
Sbjct: 138 EESVPSGE--NQSVTGGDEEVVDEYQELNAREEQDIEIMMEGCEYAISNAEFAEKL SRE 195

20 Query: 235 LQALEAANVHAILESEPLVDEVNGLAATNIVDDMDEWLGIFNIKLRHMREDIESIETR 294  
LQ L+ AN+ +I+ SE V+ ++ L+ A VD ++ L + L+ ++E ++ I  
Sbjct: 196 LQVLDGANIQSIMASEKQVNILMKLLDEALKEVDQIELKLSSYEMLQSVKEQMDQISES 255

25 Query: 295 NNKLEMQSVNNKALIEELDKVIERLRVPSEYAASLTGGSFDEADMLQNI EACEWLAKALR 354  
N+ + + + NN L+ E++ ++ + + + +L G + + IEAC A AL  
Sbjct: 256 NHLIHLSTNNVKLLSEIEFLVNHMDLAKGH IKALQEGDLASS---RGIEACTNAADALL 312

30 Query: 355 GLEVPNLDPIYANMRVKEKRAELEK LKATFVRRASEFLRNYFASLVDFMVSDKSYFSQR 414  
L P + + AVK ++ L+ F RR + L N F V S +Q  
Sbjct: 313 QCMNVALRPGHDL LLA V KQQQRFSDLR ELFARRLASHLNNVF---VQQGHDQSSTLAQH 369

35 Query: 415 G-QLKRPDHADLRYKCR TYARLLQHLKGLDKNCLGPLRKAYCSSLNLLLRREAREFAN-- 471  
+L P+H YA+L++ LK D L K Y L+ L RE ++F  
Sbjct: 370 SVELTLPNHHFPHRDLLRYAKLMEWLKSTDY GKY EGLTKNYMDYLSRLYEREIKDFFEVA 429

40 Query: 472 --ELRASTKVS-----RNPTVWLEGSTG-----SSQNANTDT 501  
++ +TK S + T L GS+G SS N + +  
Sbjct: 430 KIKMTGTTKESKKFATLPRKESAVKQETESLHGSSGKLTGSTSSLNKL SVQSSGNRRS QS 489

45 Query: 502 SAVSDA-----YAKMLTIFIPLLVD ESSFFAHFMCFEVPALAPPGG 542  
S++ D + ++L+ PL + E F + F + + PG  
Sbjct: 490 SSLDGMNMSASDL DVADRTKFDKIFEQVLSELEPLCLAEQDFISKFFKLQ-QHQSMPGT 548

50 Query: 543 AGNDKKSQSNDDGNDDDDLGIMDIDETDKKPGKNSPDLTALNESLQDLLDGIQEDFYAV 602  
E D + + + + I+ + +  
Sbjct: 549 MAEAE DLGGT LSRQHNCGTPLPV SSEKD-----MIRQMMIKIFRCIEPELNNL 597

55 Query: 603 VDAYKIDPLRCISMH-GITER YLSGQKADAAGFVRLLLGDLES RVSMQFSRFVDEACHQ 661  
+ KID + M ++ + Q D A F+ LG++ V F + + Q  
Sbjct: 598 IALGDKIDSFN SLYMLVKMSHHVWTAQNVD PASFLSTTLGNVLVTVKRNFDK CISNQIRQ 657

Query: 662 IERNERNVR-QMGVLPYIPRFAALATRMEQ-YIQGQSRDLVDQAYTKFVSIMFVTLEKIA 719  
+E + + + ++G+LP++ F A E + + R +D+AYTK + +FV +EK+A  
Sbjct: 658 MEEVKISKKSKVGILPFVAEFEEFAGLAESIFKNAERRGDL DKAYTKLIRGVFVNVEKVA 717

Query: 720 QQDPKYA-DILLLENYAAFQNSLYDLANVVPTLAKFYHQASEAYEQACTRHISMIIYYQF 778  
+ K D++++EN+ +L L + L +A + Y ++ +  
Sbjct: 718 NESQKT PRDVMMENFHHIFATLSRLK--ISCLEAEKKEAKQKYTDHLQSYVIYSLGQPL 775

10/12

## FIG. 9 Cont'd

- Query: 779 ERLFQFAKKIEDFMYT-ITPEEIPFQLGLSKVELRKMLKSSLSG-VDKSIAAMYKKLQKN 836  
 E+L F + +E + I EE+ +QL +K ELRK++K V K + +YKK+ K+  
 5 Sbjct: 776 EKLNHFFEGVEARVAQGIREEVSYQLAFNKQELRKVIKEYPGKEVKKGLDNLYKKVDKH 835
- Query: 837 LASEE-LLPSLWDKCKKEFLDKYESFVQLVAKVYPSENV 874  
 L EE LL +W + EF+ +Y+ F L+A+ YP V  
 10 Sbjct: 836 LCEEENLLQVVWHSMQDEFIRQYKHFEGLIARCYPGSGV 874
- XP 223340.1 similar to Exocyst complex component Sec3 [Rattus norvegicus]  
 Length = 571
- 15 Query: 626 SGQKADAAGFVRLLLGDLESRVSMQFSRFVDEACHQIERNERNVR-QMGVLPYIPRFAAL 684  
 + Q D A F+ LG++ V F + + Q+E + + + ++G+LP++ F  
 Sbjct: 299 TAQNVDPASFLSTTLGNVLVTVKRNFDCISNQIRQMEEVKISKKSKVGILPFVAEFEEF 358
- 20 Query: 685 ATRMEQ-YIQGQSRDLVDQAYTKFVSIMFVTLEKIAQQDPKYA-DILLLENYAAFQNSLY 742  
 A E + + R +D+AYTK + +F+ +EK+A + K D++++EN+ +L  
 Sbjct: 359 AGLAESIFKSAERRGDLDKAYTKLIRGVFINVEKVANESQKTPRDVMMENFHHIFATLS 418
- 25 Query: 743 DLANVVPTLAKFYHQASEAYEQACTRHISMIIYYQFERLFQFAKKIEDFMYT-ITPEEIP 801  
 L + L +A + Y ++ + E+L F + +E + I EE+  
 Sbjct: 419 RLK--ISCLEAEKKEAKQKYTDHLQSYVIYSLGQPLEKLNHFFEGVEARVAQGIREEEVS 476
- 30 Query: 802 FQLGLSKVELRKMLKSSLSG-VDKSIAAMYKKLQKNLASEE-LLPSLWDKCKKEFLDKYE 859  
 +QL +K ELRK++K V K + +YKK+ K+L EE LL +W + EF+ +Y+  
 Sbjct: 477 YQLAFNKQELRKVIKEYPGKEVKKGLDNLYKKVDKHLCEEENLLQVVWHSMQDEFIRQYK 536
- Query: 860 SFVQLVAKVYPSENV 874  
 F L+A+ YP V  
 Sbjct: 537 HFEGLIARCYPGSGV 551
- 35 Q8R3S6 SEC3 Mouse Exocyst complex component Sec3  
 AAH24678.1| Similar to Sec3-like [Mus musculus] Length = 894
- 40 Query: 55 LALS VKSKGPRKKAFLRMKYSSGGVLEPAKMYKLKHL SKVEVITNDPSGCTFTLGFNDL 114  
 L +V ++ P + ++V K G + + L+ L+ V+ F L F+ +  
 Sbjct: 38 LCATVTTERPVQVKVVKVKKSDKGDYKQIAWALRDLAVVDAKDAIKENPEFDLHFEKV 97
- 45 Query: 115 RSQSVAPPQWTRNTDDRNRLLVCILNICKDVLGRLPKVVGIDIVEMALWAKDNTPVVTT 174  
 +W +T ++N + CI + + L + ID V N  
 Sbjct: 98 Y-----KWVASSTAENAFISCIWKLNRQLRK-----KIDFV-----NVSSQLL 137
- 50 Query: 175 QRSTEDGEPEVAESVTESDLKVTVEKELVSQAEEEDMEALLGTYVMGIGEAFAFSERLKRE 234  
 + S GE +SV D + E + ++ EE+D+E ++ I AFAF+E+L RE  
 Sbjct: 138 EESVPSGE--NQSVAGGDEEAVDEYQELNAREEQDIEIMMEGCECAISNAEFAEKLSRE 195
- Query: 235 LQALEAANVHAILESEPLVDEVNLGLEAATNIVDDMDEWLGI FNIKLRHMRDIESIETR 294  
 LQ L+ AN+ +I+ SE V+ ++ L+ A VD ++ L + L+ ++E ++ I  
 Sbjct: 196 LQVLDGANIQSIMASEKQVNTLMQLLDEALTEVDQIELKLSSYEEMLQSVKEQMDQISES 255
- 55 Query: 295 NNKLEMQSVNNKALIEELDKVIERLRVPSEYAASLTGGSFDEADMLQNIACEWLAKALR 354  
 N+ + + + NN L+ E++ ++ + + + +L G + + IEAC A AL  
 Sbjct: 256 NHLIHLNNTNNVKKLSEIEFLVNHMDLAKGHIKALQEGDLVSS---RGIEACTNAADALL 312

11/12

## FIG. 9 Cont'd

Query: 355 GLEVPNLDPIYANMRVKEKRAELEKLGKATFVRRASEFLRNYFASLVDFMVSDKSYFSQR 414  
L P + + A K ++ L+ F RR + L N F V S +Q  
5 Sbjct: 313 QCMNVALRPGHDMLLAIKQQQQRFSDLREHFARRLASHLNNVF---VQQGHDQSSTLAQH 369  
Query: 415 G-QLKRPDHADLRYKCRITYARLLQHLKGLDKNCLGPLRKAYCSSLNNLLRREAREF 469  
+L P+H YA+L++ LK D L K Y L+ L RE ++F  
Sbjct: 370 SVELTLPNHHPFHRDLLRYAKLMEWLKSTDYGYEGLTKNYMDYLSRLYEREIKDF 425

10 AAL29126.1 SD02883p [*Drosophila melanogaster*] Length = 889

Query: 123 QWTMRNTDDRNRLVLCILN--ICKDVLGRLPKVVIGIDIVEMALWAKDNTP-VVTTQRSTE 179  
15 +W N +R L +LN I K V G+ + + A W + +P V R+ +  
Sbjct: 105 KQYALNPHERQNFLA-VLNROIQKSVRGQRAEFRNVP----AAWLSEKSPEKVALGRAVQ 159

Query: 180 DGEPVAESVTESDLKVTVEKELVSQAEEDMEALLGTYVMGIGEAFAFSERLKRELQALE 239  
+ + E + + E ++ E ++ L I +AE F E+L REL L+  
20 Sbjct: 160 KTQHM--DDEEDEEEEAQEFTALTDKEANELGKLFSECDFAIKDAEQFIEQLSRELHDL 217

Query: 240 AANVHAILESEPLVDEVNLGLEAATNIVDDMDEWLGIKRNHLMREDIESIETRNKLE 299  
AN+ ++L SE V +++ ++ A + D + L + L H++E +E I +N +E  
25 Sbjct: 218 GANMQSVLASEQKVLKMMEHIDNAISEADKFENRLDSYEDILGHVKETMEKIGGKNAMIE 277

Query: 300 MQSVNNKALIEELDKVIERLRVPSEYAASLTGGSFDEADMLQ-NIEACEWLAKALRGLEV 358  
+ + NN L++EL+KVI +L +P +L A+ + I A + L +A+  
Sbjct: 278 IANNNNIKLMKELNKVISQLDLPHSQQQALDEPDLTANGRKAAIAAAQCLQAMNS--- 334

30 Query: 359 PNLDPIYANMRVKEKRAELEKLGKATFVRRASEFLRNYFASLVDFMVSDKSYFSQRGQLK 418  
++DP + AV++++ EK K F S F+ N F L + + D S +L  
Sbjct: 335 -DIDPALLRLEAVQDQQRKRFKWKQKFSATVSRFMNNLFIHLGN-EIGDMQVTST--ELT 390

Query: 419 RPDHADLRYKCRITYARLLQHLKGLDKNCLGPLRKAYCSSLNNLLRREAREFANELRAS-T 477  
35 P+H+++ + Y L+ K +D+ L + Y +SL+ + R+ R F N + T  
Sbjct: 391 LPNHSNVHRELTPYTELMHWTKAMDRKTYDGLMRVYTASLSKIYDRDVRNFFNLAKIQVT 450

Query: 478 KVS RNPTVWLEGSTGSSQNA-----NTDTSAVSDAYAKMLTIFI 516  
+ RN L+ ST S ++A D K+L  
40 Sbjct: 451 EKLRNSREDLDMSTSSRKS AVSTIPYGT LGINRDQWGPVETADMRFDALLEKVLAELE 510

Query: 517 PLLVDESSFFAHFMCFEVPALAPPGGAGNDKKSQSNDDGNDLGLIMDIDETDKKPGK 576  
P+ + E F +F +V + P D P K  
Sbjct: 511 PIALQEQLFCINFFQMDVIS---PTTKNTQT TLEMEKAVDMTQSIISGAVSPSGDGV PQK 567

45 Query: 577 NSPDLTALNESLQDLLDG---IQEDFYAVVDWAYKIDPLRCISMH-GITERYLSGQKAD 631  
+NE ++ L+ G ++ + + + ++D + + +T+ +S Q D  
Sbjct: 568 RID--RQINEDVRKLMMGLFGCLEPELVSFISFERVDSFYSLYVVRVLTQHVMSAQ--D 623

50 Query: 632 AAGFVRLLLGDLESRVSMQFSRFVDEACHQIERNERNVRQMGVLPYIPRFAALATRMEQ- 690  
F+ + +V F RF+ I + + R +LPY+ F A E  
Sbjct: 624 THSFLSMTFASALVQVKRSFDRFMQNQLLSIREAKLHKRSKAILPYVENFENFAQTAEGI 683

Query: 691 YIQGQSRDLVDQAYTKFVSIMFVTLEKIAQQDPKYA-DILLLENYAAFQNSLYDLANVVP 749  
+ + R +++ Y + V+ +F ++ +Q+ PK ++ +ENY L L VP  
55 Sbjct: 684 FRKSDRRDMEKWYLQLVNAIFEGIQLHSQEHPKTPIQVVRMENYHHMYALLAQLK--VP 741

12/12

**FIG. 9 Cont'd**

Query: 750 TLAIFYHQASEAYEQACTRHISMIIYYQFERLFQFAKKIE-DFMYTITPEEIPFQLGLSK 808  
L +A + Y A +++ E+L QF + ++ + EI +Q+ SK  
5 Sbjct: 742 GLDALKKEAKKCYNDALKAYVTQYFGRPLEKLNQFFEGVQLKVAQGVKETEISYQMAFSK 801

Query: 809 VELRKML-KSSLGVDKSIAAMYKKLQKNLASEE-LLPSLWDKCKKEFLDKYESFVQLVA 866  
ELRK++ + V K + +YKK++K+L+ EE LL +W ++EF+ +Y + +  
10 Sbjct: 802 QELRKVIAQYPAREVKKGLENLYKKVEKHLSEENLLQVVWHAMQEEFIAQNYLEERIQ 861

Query: 867 K V Y 869  
K Y  
Sbjct: 862 K C Y 864



## SEQUENCE LISTING

<110> Quan, Pan S.

<120> Visualization of Introduced DNA in Transit by In Situ Hybridization

<130> 79811-3

<150> US 60/368,524

<151> 2002-04-01

<160> 11

<170> PatentIn version 3.2

<210> 1

<211> 887

<212> PRT

<213> Arabidopsis thaliana

<400> 1

Met Ala Lys Ser Ser Ala Asp Asp Glu Glu Leu Arg Arg Ala Cys Glu  
1 5 10 15

Ala Ala Ile Glu Gly Thr Lys Gln Ser Ile Val Met Ser Ile Arg Val  
20 25 30

Ala Lys Ser Arg Gly Val Trp Gly Lys Ser Gly Lys Leu Gly Arg Gln  
35 40 45

Met Ala Lys Pro Arg Val Leu Ala Leu Ser Val Lys Ser Lys Gly Pro  
50 55 60

Arg Lys Lys Ala Phe Leu Arg Val Met Lys Tyr Ser Ser Gly Gly Val  
65 70 75 80

Leu Glu Pro Ala Lys Met Tyr Lys Leu Lys His Leu Ser Lys Val Glu  
85 90 95

Val Ile Thr Asn Asp Pro Ser Gly Cys Thr Phe Thr Leu Gly Phe Asp  
100 105 110

Asn Leu Arg Ser Gln Ser Val Ala Pro Pro Gln Trp Thr Met Arg Asn  
115 120 125

Thr Asp Asp Arg Asn Arg Leu Leu Val Cys Ile Leu Asn Ile Cys Lys  
130 135 140

Asp Val Leu Gly Arg Leu Pro Lys Val Val Gly Ile Asp Ile Val Glu  
145 150 155 160

Met Ala Leu Trp Ala Lys Asp Asn Thr Pro Val Val Thr Thr Gln Arg  
 165 170 175

Ser Thr Glu Asp Gly Glu Pro Val Ala Glu Ser Val Thr Glu Ser Asp  
 180 185 190

Leu Lys Val Thr Val Glu Lys Glu Leu Val Ser Gln Ala Glu Glu Glu  
 195 200 205

Asp Met Glu Ala Leu Leu Gly Thr Tyr Val Met Gly Ile Gly Glu Ala  
 210 215 220

Glu Ala Phe Ser Glu Arg Leu Lys Arg Glu Leu Gln Ala Leu Glu Ala  
 225 230 235 240

Ala Asn Val His Ala Ile Leu Glu Ser Glu Pro Leu Val Asp Glu Val  
 245 250 255

Leu Asn Gly Leu Glu Ala Ala Thr Asn Ile Val Asp Asp Met Asp Glu  
 260 265 270

Trp Leu Gly Ile Phe Asn Ile Lys Leu Arg His Met Arg Glu Asp Ile  
 275 280 285

Glu Ser Ile Glu Thr Arg Asn Asn Lys Leu Glu Met Gln Ser Val Asn  
 290 295 300

Asn Lys Ala Leu Ile Glu Glu Leu Asp Lys Val Ile Glu Arg Leu Arg  
 305 310 315 320

Val Pro Ser Glu Tyr Ala Ala Ser Leu Thr Gly Gly Ser Phe Asp Glu  
 325 330 335

Ala Asp Met Leu Gln Asn Ile Glu Ala Cys Glu Trp Leu Ala Lys Ala  
 340 345 350

Leu Arg Gly Leu Glu Val Pro Asn Leu Asp Pro Ile Tyr Ala Asn Met  
 355 360 365

Arg Ala Val Lys Glu Lys Arg Ala Glu Leu Glu Lys Leu Lys Ala Thr  
 370 375 380

Phe Val Arg Arg Ala Ser Glu Phe Leu Arg Asn Tyr Phe Ala Ser Leu  
 385 390 395 400

Val Asp Phe Met Val Ser Asp Lys Ser Tyr Phe Ser Gln Arg Gly Gln

	405		410		415
Leu Lys Arg Pro Asp His Ala Asp Leu Arg Tyr Lys Cys Arg Thr Tyr	420		425		430
Ala Arg Leu Leu Gln His Leu Lys Gly Leu Asp Lys Asn Cys Leu Gly	435		440		445
Pro Leu Arg Lys Ala Tyr Cys Ser Ser Leu Asn Leu Leu Leu Arg Arg	450		455		460
Glu Ala Arg Glu Phe Ala Asn Glu Leu Arg Ala Ser Thr Lys Val Ser	465		470		475
Arg Asn Pro Thr Val Trp Leu Glu Gly Ser Thr Gly Ser Ser Gln Asn	485		490		495
Ala Asn Thr Asp Thr Ser Ala Val Ser Asp Ala Tyr Ala Lys Met Leu	500		505		510
Thr Ile Phe Ile Pro Leu Leu Val Asp Glu Ser Ser Phe Phe Ala His	515		520		525
Phe Met Cys Phe Glu Val Pro Ala Leu Ala Pro Pro Gly Gly Ala Gly	530		535		540
Asn Asp Lys Lys Ser Gln Ser Asn Asn Asp Asp Gly Asn Asp Asp Asp	545		550		555
Asp Leu Gly Ile Met Asp Ile Asp Glu Thr Asp Lys Lys Pro Gly Lys	565		570		575
Asn Ser Pro Asp Leu Thr Ala Leu Asn Glu Ser Leu Gln Asp Leu Leu	580		585		590
Asp Gly Ile Gln Glu Asp Phe Tyr Ala Val Val Asp Trp Ala Tyr Lys	595		600		605
Ile Asp Pro Leu Arg Cys Ile Ser Met His Gly Ile Thr Glu Arg Tyr	610		615		620
Leu Ser Gly Gln Lys Ala Asp Ala Ala Gly Phe Val Arg Leu Leu Leu	625		630		635
Gly Asp Leu Glu Ser Arg Val Ser Met Gln Phe Ser Arg Phe Val Asp	645		650		655

Glu Ala Cys His Gln Ile Glu Arg Asn Glu Arg Asn Val Arg Gln Met  
660 665 670

Gly Val Leu Pro Tyr Ile Pro Arg Phe Ala Ala Leu Ala Thr Arg Met  
675 680 685

Glu Gln Tyr Ile Gln Gly Gln Ser Arg Asp Leu Val Asp Gln Ala Tyr  
690 695 700

Thr Lys Phe Val Ser Ile Met Phe Val Thr Leu Glu Lys Ile Ala Gln  
705 710 715 720

Gln Asp Pro Lys Tyr Ala Asp Ile Leu Leu Leu Glu Asn Tyr Ala Ala  
725 730 735

Phe Gln Asn Ser Leu Tyr Asp Leu Ala Asn Val Val Pro Thr Leu Ala  
740 745 750

Lys Phe Tyr His Gln Ala Ser Glu Ala Tyr Glu Gln Ala Cys Thr Arg  
755 760 765

His Ile Ser Met Ile Ile Tyr Tyr Gln Phe Glu Arg Leu Phe Gln Phe  
770 775 780

Ala Lys Lys Ile Glu Asp Phe Met Tyr Thr Ile Thr Pro Glu Glu Ile  
785 790 795 800

Pro Phe Gln Leu Gly Leu Ser Lys Val Glu Leu Arg Lys Met Leu Lys  
805 810 815

Ser Ser Leu Ser Gly Val Asp Lys Ser Ile Ala Ala Met Tyr Lys Lys  
820 825 830

Leu Gln Lys Asn Leu Ala Ser Glu Glu Leu Leu Pro Ser Leu Trp Asp  
835 840 845

Lys Cys Lys Lys Glu Phe Leu Asp Lys Tyr Glu Ser Phe Val Gln Leu  
850 855 860

Val Ala Lys Val Tyr Pro Ser Glu Asn Val Pro Gly Val Thr Glu Met  
865 870 875 880

Arg Gly Leu Leu Ala Ser Met  
885

<210> 2  
<211> 15  
<212> DNA  
<213> Artificial

<220>  
<223> GUS-1 primer

<400> 2  
cgtcctgtag aaacc  
15

<210> 3  
<211> 15  
<212> DNA  
<213> Artificial

<220>  
<223> GUS-2 primer

<400> 3  
acgcacagtt catag  
15

<210> 4  
<211> 15  
<212> DNA  
<213> Artificial

<220>  
<223> BIN19-1 primer

<400> 4  
ttgctcatgt taccg  
15

<210> 5  
 <211> 15  
 <212> DNA  
 <213> Artificial

<220>  
 <223> BIN19-2 primer

<400> 5  
 gcagttccgc aaata  
 15

<210> 6  
 <211> 27  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Oligo-105 primer

<400> 6  
 gaagaattcg aacttgacgc cgatacc  
 27

<210> 7  
 <211> 24  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Oligo-107 primer

<400> 7  
 aggctgcaga catgcgtatt ttcg  
 24

<210> 8  
 <211> 894  
 <212> PRT  
 <213> Homo sapiens

<400> 8

Met	Thr	Ala	Ile	Lys	His	Ala	Leu	Gln	Arg	Asp	Ile	Phe	Thr	Pro	Asn
1				5					10					15	

Asp	Glu	Arg	Leu	Leu	Ser	Ile	Val	Asn	Val	Cys	Lys	Ala	Gly	Lys	Lys
			20					25					30		

Lys	Lys	Asn	Cys	Phe	Leu	Cys	Ala	Thr	Val	Thr	Thr	Glu	Arg	Pro	Val
		35					40					45			

Gln	Val	Lys	Val	Val	Lys	Val	Lys	Lys	Ser	Asp	Lys	Gly	Asp	Phe	Tyr
	50					55					60				

Lys Arg Gln Ile Ala Trp Ala Leu Arg Asp Leu Ala Val Val Asp Ala

65		70		75		80									
Lys	Asp	Ala	Ile	Lys	Glu	Asn	Pro	Glu	Phe	Asp	Leu	His	Phe	Glu	Lys
				85					90					95	
Ile	Tyr	Lys	Trp	Val	Ala	Ser	Ser	Thr	Ala	Glu	Lys	Asn	Ala	Phe	Ile
			100					105					110		
Ser	Cys	Ile	Trp	Lys	Leu	Asn	Gln	Arg	Tyr	Leu	Arg	Lys	Lys	Ile	Asp
		115					120					125			
Phe	Val	Asn	Val	Ser	Ser	Gln	Leu	Leu	Glu	Glu	Ser	Val	Pro	Ser	Gly
	130					135					140				
Glu	Asn	Gln	Ser	Val	Thr	Gly	Gly	Asp	Glu	Glu	Val	Val	Asp	Glu	Tyr
145					150					155					160
Gln	Glu	Leu	Asn	Ala	Arg	Glu	Glu	Gln	Asp	Ile	Glu	Ile	Met	Met	Glu
				165					170					175	
Gly	Cys	Glu	Tyr	Ala	Ile	Ser	Asn	Ala	Glu	Ala	Phe	Ala	Glu	Lys	Leu
			180					185					190		
Ser	Arg	Glu	Leu	Gln	Val	Leu	Asp	Gly	Ala	Asn	Ile	Gln	Ser	Ile	Met
		195					200					205			
Ala	Ser	Glu	Lys	Gln	Val	Asn	Ile	Leu	Met	Lys	Leu	Leu	Asp	Glu	Ala
	210					215					220				
Leu	Lys	Glu	Val	Asp	Gln	Ile	Glu	Leu	Lys	Leu	Ser	Ser	Tyr	Glu	Glu
225					230					235					240
Met	Leu	Gln	Ser	Val	Lys	Glu	Gln	Met	Asp	Gln	Ile	Ser	Glu	Ser	Asn
				245					250					255	
His	Leu	Ile	His	Leu	Ser	Asn	Thr	Asn	Asn	Val	Lys	Leu	Leu	Ser	Glu
		260						265					270		
Ile	Glu	Phe	Leu	Val	Asn	His	Met	Asp	Leu	Ala	Lys	Gly	His	Ile	Lys
	275						280					285			
Ala	Leu	Gln	Glu	Gly	Asp	Leu	Ala	Ser	Ser	Arg	Gly	Ile	Glu	Ala	Cys
	290					295					300				
Thr	Asn	Ala	Ala	Asp	Ala	Leu	Leu	Gln	Cys	Met	Asn	Val	Ala	Leu	Arg
305					310					315					320

Pro Gly His Asp Leu Leu Leu Ala Val Lys Gln Gln Gln Gln Arg Phe  
 325 330 335

Ser Asp Leu Arg Glu Leu Phe Ala Arg Arg Leu Ala Ser His Leu Asn  
 340 345 350

Asn Val Phe Val Gln Gln Gly His Asp Gln Ser Ser Thr Leu Ala Gln  
 355 360 365

His Ser Val Glu Leu Thr Leu Pro Asn His His Pro Phe His Arg Asp  
 370 375 380

Leu Leu Arg Tyr Ala Lys Leu Met Glu Trp Leu Lys Ser Thr Asp Tyr  
 385 390 395 400

Gly Lys Tyr Glu Gly Leu Thr Lys Asn Tyr Met Asp Tyr Leu Ser Arg  
 405 410 415

Leu Tyr Glu Arg Glu Ile Lys Asp Phe Phe Glu Val Ala Lys Ile Lys  
 420 425 430

Met Thr Gly Thr Thr Lys Glu Ser Lys Lys Phe Ala Thr Leu Pro Arg  
 435 440 445

Lys Glu Ser Ala Val Lys Gln Glu Thr Glu Ser Leu His Gly Ser Ser  
 450 455 460

Gly Lys Leu Thr Gly Ser Thr Ser Ser Leu Asn Lys Leu Ser Val Gln  
 465 470 475 480

Ser Ser Gly Asn Arg Arg Ser Gln Ser Ser Ser Leu Leu Asp Met Gly  
 485 490 495

Asn Met Ser Ala Ser Asp Leu Asp Val Ala Asp Arg Thr Lys Phe Asp  
 500 505 510



Lys Ile Phe Glu Gln Val Leu Ser Glu Leu Glu Pro Leu Cys Leu Ala  
 515 520 525

Glu Gln Asp Phe Ile Ser Lys Phe Phe Lys Leu Gln Gln His Gln Ser  
 530 535 540

Met Pro Gly Thr Met Ala Glu Ala Glu Asp Leu Asp Gly Gly Thr Leu  
 545 550 555 560

Ser Arg Gln His Asn Cys Gly Thr Pro Leu Pro Val Ser Ser Glu Lys  
 565 570 575

Asp Met Ile Arg Gln Met Met Ile Lys Ile Phe Arg Cys Ile Glu Pro  
 580 585 590

Glu Leu Asn Asn Leu Ile Ala Leu Gly Asp Lys Ile Asp Ser Phe Asn  
 595 600 605

Ser Leu Tyr Met Leu Val Lys Met Ser His His Val Trp Thr Ala Gln  
 610 615 620

Asn Val Asp Pro Ala Ser Phe Leu Ser Thr Thr Leu Gly Asn Val Leu  
 625 630 635 640

Val Thr Val Lys Arg Asn Phe Asp Lys Cys Ile Ser Asn Gln Ile Arg  
 645 650 655

Gln Met Glu Glu Val Lys Ile Ser Lys Lys Ser Lys Val Gly Ile Leu  
 660 665 670

Pro Phe Val Ala Glu Phe Glu Glu Phe Ala Gly Leu Ala Glu Ser Ile  
 675 680 685

Phe Lys Asn Ala Glu Arg Arg Gly Asp Leu Asp Lys Ala Tyr Thr Lys  
 690 695 700

Leu Ile Arg Gly Val Phe Val Asn Val Glu Lys Val Ala Asn Glu Ser  
 705 710 715 720

Gln Lys Thr Pro Arg Asp Val Val Met Met Glu Asn Phe His His Ile  
 725 730 735

Phe Ala Thr Leu Ser Arg Leu Lys Ile Ser Cys Leu Glu Ala Glu Lys  
740 745 750

Lys Glu Ala Lys Gln Lys Tyr Thr Asp His Leu Gln Ser Tyr Val Ile  
755 760 765

Tyr Ser Leu Gly Gln Pro Leu Glu Lys Leu Asn His Phe Phe Glu Gly  
770 775 780

Val Glu Ala Arg Val Ala Gln Gly Ile Arg Glu Glu Glu Val Ser Tyr  
785 790 795 800

Gln Leu Ala Phe Asn Lys Gln Glu Leu Arg Lys Val Ile Lys Glu Tyr  
805 810 815

Pro Gly Lys Glu Val Lys Lys Gly Leu Asp Asn Leu Tyr Lys Lys Val  
820 825 830

Asp Lys His Leu Cys Glu Glu Glu Asn Leu Leu Gln Val Val Trp His  
835 840 845

Ser Met Gln Asp Glu Phe Ile Arg Gln Tyr Lys His Phe Glu Gly Leu  
850 855 860

Ile Ala Arg Cys Tyr Pro Gly Ser Gly Val Thr Met Glu Phe Thr Ile  
865 870 875 880

Gln Asp Ile Leu Asp Tyr Cys Ser Ser Ile Ala Gln Ser His  
885 890

<210> 9

<211> 571

<212> PRT

<213> Rattus norvegicus

<400> 9

Met Met Pro Val Ala Ser Ser Leu Ile Lys Met Pro Gly Leu Phe His  
1 5 10 15

Pro Val Ile Arg Pro Trp Glu Ile Pro Lys Gly Pro Glu Ile Arg Asn  
20 25 30

Thr Val Ile Pro Asn Thr Asp Thr Thr Ser Gly Ser Phe Asn Tyr Met  
35 40 45

Asp Tyr Leu Ser Arg Leu Tyr Glu Arg Glu Ile Lys Asp Phe Phe Glu  
50 55 60

Val	Ala	Lys	Met	Lys	Met	Thr	Gly	Thr	Thr	Lys	Glu	Ser	Lys	Lys	Phe	65	70	75	80
Ala	Thr	Leu	Pro	Arg	Lys	Glu	Ser	Ala	Val	Lys	Gln	Glu	Thr	Glu	Arg	85	90	95	
Met	Ser	Gln	Gly	Arg	Val	Ser	Cys	Ser	Val	Ser	Thr	Val	Leu	Ser	Asp	100	105	110	
Pro	His	Arg	Cys	Pro	Ile	Cys	Phe	Gly	Leu	Glu	Ser	Thr	Ile	Ala	Leu	115	120	125	
Pro	Ser	Gly	Gln	Asp	Pro	Val	Ser	Leu	His	Gly	Ser	Ser	Gly	Lys	Leu	130	135	140	
Thr	Gly	Ser	Thr	Ser	Ser	Leu	Asn	Lys	Leu	Ser	Val	Gln	Ser	Ser	Gly	145	150	155	160
Ser	Arg	Arg	Ser	Gln	Ser	Ser	Ser	Leu	Leu	Asp	Met	Gly	Asn	Met	Ser	165	170	175	
Ala	Ser	Asp	Leu	Asp	Val	Ala	Asp	Arg	Thr	Lys	Phe	Asp	Lys	Ile	Phe	180	185	190	
Glu	Gln	Val	Leu	Ser	Glu	Leu	Glu	Pro	Leu	Cys	Leu	Ala	Glu	Gln	Asp	195	200	205	
Phe	Ile	Ser	Lys	Phe	Phe	Lys	Leu	Gln	Gln	His	Gln	Asn	Leu	Ser	Ala	210	215	220	
Ser	Met	Ala	Glu	Ala	Glu	Asp	Leu	Asp	Gly	Gly	Ser	Leu	Ser	Arg	Pro	225	230	235	240
Gln	Ser	Ser	Gly	Ser	Leu	Leu	Pro	Val	Ser	Ser	Glu	Lys	Asp	Met	Ile	245	250	255	
Arg	Gln	Met	Met	Ile	Lys	Ile	Phe	Arg	Cys	Ile	Glu	Pro	Glu	Leu	Asn	260	265	270	
Asn	Leu	Ile	Ala	Leu	Gly	Asp	Lys	Val	Asp	Ser	Phe	Asn	Ser	Leu	Tyr	275	280	285	
Met	Leu	Val	Lys	Met	Ser	His	His	Val	Trp	Thr	Ala	Gln	Asn	Val	Asp	290	295	300	
Pro	Ala	Ser	Phe	Leu	Ser	Thr	Thr	Leu	Gly	Asn	Val	Leu	Val	Thr	Val				

305		310		315		320
Lys Arg Asn Phe Asp Lys Cys Ile Ser Asn Gln Ile Arg Gln Met Glu						
		325		330		335
Glu Val Lys Ile Ser Lys Lys Ser Lys Val Gly Ile Leu Pro Phe Val						
		340		345		350
Ala Glu Phe Glu Glu Phe Ala Gly Leu Ala Glu Ser Ile Phe Lys Ser						
		355		360		365
Ala Glu Arg Arg Gly Asp Leu Asp Lys Ala Tyr Thr Lys Leu Ile Arg						
		370		375		380
Gly Val Phe Ile Asn Val Glu Lys Val Ala Asn Glu Ser Gln Lys Thr						
		385		390		400
Pro Arg Asp Val Val Met Met Glu Asn Phe His His Ile Phe Ala Thr						
		405		410		415
Leu Ser Arg Leu Lys Ile Ser Cys Leu Glu Ala Glu Lys Lys Glu Ala						
		420		425		430
Lys Gln Lys Tyr Thr Asp His Leu Gln Ser Tyr Val Ile Tyr Ser Leu						
		435		440		445
Gly Gln Pro Leu Glu Lys Leu Asn His Phe Phe Glu Gly Val Glu Ala						
		450		455		460
Arg Val Ala Gln Gly Ile Arg Glu Glu Glu Val Ser Tyr Gln Leu Ala						
		465		470		480
Phe Asn Lys Gln Glu Leu Arg Lys Val Ile Lys Glu Tyr Pro Gly Lys						
		485		490		495
Glu Val Lys Lys Gly Leu Asp Asn Leu Tyr Lys Lys Val Asp Lys His						
		500		505		510
Leu Cys Glu Glu Glu Asn Leu Leu Gln Val Val Trp His Ser Met Gln						
		515		520		525
Asp Glu Phe Ile Arg Gln Tyr Lys His Phe Glu Gly Leu Ile Ala Arg						
		530		535		540
Cys Tyr Pro Gly Ser Gly Val Thr Met Glu Phe Thr Ile Gln Asp Ile						
		545		550		555
						560

Leu Asp Tyr Cys Ser Ser Ile Ala Gln Ser His  
                                   565                                  570

<210> 10  
 <211> 894  
 <212> PRT  
 <213> Mus musculus

<400> 10

Met Thr Ala Ile Lys His Ala Leu Gln Arg Asp Ile Phe Thr Pro Asn  
 1                                  5                                  10                                  15

Asp Glu Arg Leu Leu Ser Ile Val Asn Val Cys Lys Ala Gly Lys Lys  
                                   20                                  25                                  30

Lys Lys Asn Cys Phe Leu Cys Ala Thr Val Thr Thr Glu Arg Pro Val  
                                   35                                  40                                  45

Gln Val Lys Val Val Lys Val Lys Lys Ser Asp Lys Gly Asp Phe Tyr  
                                   50                                  55                                  60

Lys Arg Gln Ile Ala Trp Ala Leu Arg Asp Leu Ala Val Val Asp Ala  
 65                                  70                                  75                                  80

Lys Asp Ala Ile Lys Glu Asn Pro Glu Phe Asp Leu His Phe Glu Lys  
                                   85                                  90                                  95

Val Tyr Lys Trp Val Ala Ser Ser Thr Ala Glu Lys Asn Ala Phe Ile  
                                   100                                  105                                  110

Ser Cys Ile Trp Lys Leu Asn Gln Arg Tyr Leu Arg Lys Lys Ile Asp  
                                   115                                  120                                  125

Phe Val Asn Val Ser Ser Gln Leu Leu Glu Glu Ser Val Pro Ser Gly  
                                   130                                  135                                  140

Glu Asn Gln Ser Val Ala Gly Gly Asp Glu Glu Ala Val Asp Glu Tyr  
 145                                  150                                  155                                  160

Gln Glu Leu Asn Ala Arg Glu Glu Gln Asp Ile Glu Ile Met Met Glu  
                                   165                                  170                                  175

Gly Cys Glu Cys Ala Ile Ser Asn Ala Glu Ala Phe Ala Glu Lys Leu  
                                   180                                  185                                  190

Ser Arg Glu Leu Gln Val Leu Asp Gly Ala Asn Ile Gln Ser Ile Met  
                                   195                                  200                                  205

Ala Ser Glu Lys Gln Val Asn Thr Leu Met Gln Leu Leu Asp Glu Ala  
 210 215 220

Leu Thr Glu Val Asp Gln Ile Glu Leu Lys Leu Ser Ser Tyr Glu Glu  
 225 230 235 240

Met Leu Gln Ser Val Lys Glu Gln Met Asp Gln Ile Ser Glu Ser Asn  
 245 250 255

His Leu Ile His Leu Ser Asn Thr Asn Asn Val Lys Leu Leu Ser Glu  
 260 265 270

Ile Glu Phe Leu Val Asn His Met Asp Leu Ala Lys Gly His Ile Lys  
 275 280 285

Ala Leu Gln Glu Gly Asp Leu Val Ser Ser Arg Gly Ile Glu Ala Cys  
 290 295 300

Thr Asn Ala Ala Asp Ala Leu Leu Gln Cys Met Asn Val Ala Leu Arg  
 305 310 315 320

Pro Gly His Asp Met Leu Leu Ala Ile Lys Gln Gln Gln Gln Arg Phe  
 325 330 335

Ser Asp Leu Arg Glu His Phe Ala Arg Arg Leu Ala Ser His Leu Asn  
 340 345 350

Asn Val Phe Val Gln Gln Gly His Asp Gln Ser Ser Thr Leu Ala Gln  
 355 360 365

His Ser Val Glu Leu Thr Leu Pro Asn His His Pro Phe His Arg Asp  
 370 375 380

Leu Leu Arg Tyr Ala Lys Leu Met Glu Trp Leu Lys Ser Thr Asp Tyr  
 385 390 395 400

Gly Lys Tyr Glu Gly Leu Thr Lys Asn Tyr Met Asp Tyr Leu Ser Arg  
 405 410 415

Leu Tyr Glu Arg Glu Ile Lys Asp Phe Phe Glu Val Ala Lys Met Lys  
 420 425 430

Met Thr Gly Thr Ser Lys Glu Ser Lys Lys Phe Ala Thr Leu Pro Arg  
 435 440 445

Lys Glu Ser Ala Val Lys Gln Glu Thr Glu Ser Leu His Gly Ser Ser  
 450 455 460

Gly Lys Leu Thr Gly Ser Thr Ser Ser Leu Asn Lys Leu Ser Val Gln  
 465 470 475 480

Ser Ser Gly Ser Arg Arg Ser Gln Ser Ser Ser Leu Leu Asp Met Gly  
 485 490 495

Asn Met Ser Ala Ser Asp Leu Asp Val Ala Asp Arg Thr Lys Phe Asp  
 500 505 510

Lys Ile Phe Glu Gln Val Leu Ser Glu Leu Glu Pro Leu Cys Leu Ala  
 515 520 525

Glu Gln Asp Phe Ile Ser Lys Phe Phe Lys Leu Gln Gln His Gln Asn  
 530 535 540

Met Ser Ala Ser Met Thr Glu Ala Glu Asp Leu Asp Gly Gly Ser Leu  
 545 550 555 560

Ser Arg Gln His Ser Ser Gly Thr Leu Leu Pro Val Ser Ser Glu Lys  
 565 570 575

Asp Met Ile Arg Gln Met Met Ile Lys Ile Phe Arg Cys Ile Glu Pro  
 580 585 590

Glu Leu Asn Asn Leu Ile Ala Leu Gly Asp Lys Val Asp Ser Phe Asn  
 595 600 605

Ser Leu Tyr Met Leu Val Lys Met Ser His His Val Trp Thr Ala Gln  
 610 615 620

Asn Val Asp Pro Ala Ser Phe Leu Ser Thr Thr Leu Gly Asn Val Leu  
 625 630 635 640

Val Thr Val Lys Arg Asn Phe Asp Lys Cys Ile Ser Asn Gln Ile Arg  
 645 650 655

Gln Met Glu Glu Val Lys Ile Ser Lys Lys Ser Lys Val Gly Ile Leu  
 660 665 670

Pro Phe Val Ala Glu Phe Glu Glu Phe Ala Gly Leu Ala Glu Ser Ile  
 675 680 685

Phe Lys Asn Ala Glu Arg Arg Gly Asp Leu Asp Lys Ala Tyr Thr Lys  
 690 695 700

Leu Ile Arg Gly Val Phe Ile Asn Val Glu Lys Val Ala Asn Glu Ser  
705 710 715 720

Gln Lys Thr Pro Arg Asp Val Val Met Met Glu Asn Phe His His Ile  
725 730 735

Phe Ala Thr Leu Ser Arg Leu Lys Ile Ser Cys Leu Glu Ala Glu Lys  
740 745 750

Lys Glu Ala Lys Gln Lys Tyr Thr Asp His Leu Gln Ser Tyr Val Ile  
755 760 765

Tyr Ser Leu Gly Gln Pro Leu Glu Lys Leu Asn His Phe Phe Glu Gly  
770 775 780

Val Glu Ala Arg Val Ala Gln Gly Ile Arg Glu Glu Glu Val Ser Tyr  
785 790 795 800



Gln Leu Ala Phe Asn Lys Gln Glu Leu Arg Lys Val Ile Lys Glu Tyr  
 805 810 815

Pro Gly Lys Glu Val Lys Lys Gly Leu Asp Asn Leu Tyr Lys Lys Val  
 820 825 830

Asp Lys His Leu Cys Glu Glu Glu Asn Leu Leu Gln Val Val Trp His  
 835 840 845

Ser Met Gln Asp Glu Phe Ile Arg Gln Tyr Lys His Phe Glu Gly Leu  
 850 855 860

Ile Ala Arg Cys Tyr Pro Gly Ser Gly Val Thr Met Glu Phe Thr Ile  
 865 870 875 880

Gln Asp Ile Leu Asp Tyr Cys Ser Ser Ile Ala Gln Ser His  
 885 890

<210> 11  
 <211> 889  
 <212> PRT  
 <213> *Drosophila melanogaster*

<400> 11

Met Leu Ser Ile Gly Ala Met Ala Asn Ile Lys His Thr Leu Gln Lys  
 1 5 10 15

Glu Leu Phe Leu Ala Ser Gly Glu Arg Leu Leu Ser Val Val Thr Val  
 20 25 30

Val Lys Lys Lys Asp Lys Lys Pro Cys Tyr Leu Cys Val Val Thr Thr  
 35 40 45

Ala Pro Pro Val Pro Val Val Thr Leu Cys Leu Ile Lys Gln Ser Glu  
 50 55 60

Gln Arg Glu Gly Glu Tyr Lys Arg Lys Arg Ser Trp Gln Leu Asp Glu  
 65 70 75 80

Ile Lys Trp Val Asp Gly Arg Asn Glu Gln Phe Gln Thr His Glu Phe  
 85 90 95

Asp Leu Gln Leu Glu Lys Leu Tyr Lys Trp Tyr Ala Leu Asn Pro His  
 100 105 110

Glu Arg Gln Asn Phe Leu Ala Val Leu Asn Arg Gln Ile Gln Lys Ser  
 115 120 125

Val Arg Gly Gln Arg Ala Glu Phe Arg Asn Val Pro Ala Ala Trp Leu  
 130 135 140

Ser Glu Lys Ser Pro Glu Lys Val Ala Leu Gly Arg Ala Val Gln Lys  
 145 150 155 160

Thr Gln His Met Asp Asp Glu Glu Asp Glu Glu Glu Glu Ala Gln Glu  
 165 170 175

Phe Thr Ala Leu Thr Asp Lys Glu Ala Asn Glu Leu Gly Lys Leu Phe  
 180 185 190

Ser Glu Cys Asp Phe Ala Ile Lys Asp Ala Glu Gln Phe Ile Glu Gln  
 195 200 205

Leu Ser Arg Glu Leu His Asp Leu Asp Gly Ala Asn Met Gln Ser Val  
 210 215 220

Leu Ala Ser Glu Gln Lys Val Leu Lys Met Met Glu His Ile Asp Asn  
 225 230 235 240

Ala Ile Ser Glu Ala Asp Lys Phe Glu Asn Arg Leu Asp Ser Tyr Glu  
 245 250 255

Asp Ile Leu Gly His Val Lys Glu Thr Met Glu Lys Ile Gly Gly Lys  
 260 265 270

Asn Ala Met Ile Glu Ile Ala Asn Asn Asn Asn Ile Lys Leu Met Lys  
 275 280 285

Glu Leu Asn Lys Val Ile Ser Gln Leu Asp Leu Pro His Ser Gln Gln  
 290 295 300

Gln Ala Leu Asp Glu Pro Asp Leu Lys Thr Ala Asn Gly Arg Lys Ala  
 305 310 315 320

Ala Ile Ala Ala Ala Gln Cys Leu Gln Gln Ala Met Asn Ser Asp Ile  
 325 330 335

Asp Pro Ala Leu Leu Arg Leu Glu Ala Val Gln Asp Gln Arg Lys Arg  
 340 345 350

Phe Glu Lys Trp Lys Gln Lys Phe Ser Ala Thr Val Ser Arg Phe Met  
 355 360 365

Asn Asn Leu Phe Ile His Leu Gly Asn Glu Ile Gly Asp Met Gln Val

Tyr Val Phe Val Arg Leu Thr Gln His Val Met Ser Ala Gln Asp Thr  
610 615 620

His Ser Phe Leu Ser Met Thr Phe Ala Ser Ala Leu Val Gln Val Lys  
625 630 635 640

Arg Ser Phe Asp Arg Phe Met Gln Asn Gln Leu Leu Ser Ile Arg Glu  
645 650 655

Ala Lys Leu His Lys Arg Ser Lys Ala Ile Leu Pro Tyr Val Glu Asn  
660 665 670

Phe Glu Asn Phe Ala Gln Thr Ala Glu Gly Ile Phe Arg Lys Ser Asp  
675 680 685

Arg Arg Thr Asp Met Glu Lys Trp Tyr Leu Gln Leu Val Asn Ala Ile  
690 695 700

Phe Glu Gly Ile Gln Leu His Ser Gln Glu His Pro Lys Thr Pro Ile  
705 710 715 720

Gln Val Val Arg Met Glu Asn Tyr His His Met Tyr Ala Leu Leu Ala  
725 730 735

Gln Leu Lys Val Pro Gly Leu Asp Ala Leu Lys Lys Glu Ala Lys Lys  
740 745 750

Cys Tyr Asn Asp Ala Leu Lys Ala Tyr Val Thr Gln Tyr Phe Gly Arg  
755 760 765

Pro Leu Glu Lys Leu Asn Gln Phe Phe Glu Gly Val Gln Leu Lys Val  
770 775 780

Ala Gln Gly Val Lys Glu Thr Glu Ile Ser Tyr Gln Met Ala Phe Ser  
785 790 795 800

Lys Gln Glu Leu Arg Lys Val Ile Ala Gln Tyr Pro Ala Arg Glu Val  
805 810 815

Lys Lys Gly Leu Glu Asn Leu Tyr Lys Lys Val Glu Lys His Leu Ser  
820 825 830

Glu Glu Glu Asn Leu Leu Gln Val Val Trp His Ala Met Gln Glu Glu  
835 840 845

Phe Ile Ala Gln Tyr Asn Tyr Leu Glu Glu Arg Ile Gln Lys Cys Tyr  
850 855 860

Ala Gly Ala Met Ile Asn Leu Glu Phe Asn Ile Gln Asp Ile Leu Ala  
865 870 875 880

Phe Phe Ser Asp Ile Ala Arg Ser His  
885

**A. CLASSIFICATION OF SUBJECT MATTER**Int. Cl. <sup>7</sup>: C12Q 1/02, 1/68; G01N 33/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

SEE ELECTRONIC DATABASE BOX BELOW

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SEE ELECTRONIC DATABASE BOX BELOW

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPIDS, Medline, CA: in situ hybrid?, exogenous, time course, kinetic, multiple, monitor, locate, transit

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X/Y	PATIL, J. G. and KHOO, H. W. (1996) "Nuclear Internalization of Foreign DNA by Zebrafish Spermatozoa and Its Enhancement by Electroporation" <i>The Journal of Experimental Zoology</i> 274:121-129. See entire document, particularly Figure 6.	1-27
X/Y	CHEN, C and CHASIN, L. A. (1998) "Cointegration of DNA Molecules Introduced into Mammalian Cells by Electroporation" <i>Somatic Cell and Molecular Genetics</i> 24(4):249-256. See entire document, particularly results and Figure 2	1-27
X/Y	AINGER, K. et al (1993) "Transport and Localization of Exogenous Myelin Basic Protein mRNA Microinjected into Oligodendrocytes" <i>The Journal of Cell Biology</i> 123(2):431-441 See entire document	1-27



Further documents are listed in the continuation of Box C



See patent family annex

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"J" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

14 May 2003

Date of mailing of the international search report

22 MAY 2003

Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE  
PO BOX 200, WODEN ACT 2606, AUSTRALIA  
E-mail address: pct@ipaaustralia.gov.au  
Facsimile No. (02) 6285 3929

Authorized officer

**PHILIPPA WYRDEMAN**  
Telephone No : (02) 6283 2554

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**